
















The British military was engaged in combat operations in Iraq and Afghanistan over a 
12-year period from 2003 to 2014. It has been asserted that over this time survival 
after combat injury improved generating a cohort of patients with complex limb 
injuries, including open fractures, which are prone to infection and challenging to 
reconstruct. 
 
Using an anatomic measure of injury severity I demonstrate an improvement in 
survival after combat injury. I further tested this finding by devising a military specific 
version of an anatomic-physiological injury scoring system, which confirmed the 
survival improvement.  
 
The UK military trauma registry was used to determine that the most frequently 
fractured bone was the Tibia and 65% of these fractures were open. Of these, 23% 
were surgically treated for infection in the first year and S. aureus bacteria was the 
causative organism in 60%. Infection was significantly associated with amputation or 
unplanned revision surgery. 
 
To further investigate open fracture infections in a controlled setting, an established 
rodent model of a stabilised, S. aureus contaminated, femoral defect was refined. 
This model was used to investigate the relationship between timing of treatment and 
infection. The results of this study indicate that delaying antibiotics administration has 
a greater effect on infection rates than delaying surgery and that early antibiotics can 
reduce the greater infection seen with surgical delay but not negate its effect entirely. 
 
Novel treatments with potential to reduce infection in open fractures were then 
evaluated. Chlorhexidine was found to be similar to saline for wound irrigation with 
respect to preventing infection. A novel biodegradable antibiotic gel proved to be 
superior at preventing infection in the model than the existing clinical standard local 
antibiotic delivery vehicle: bone cement (Polymethylmethacrylate) beads. Finally 

































































Dedication and Thanks 
 
 
Surg Lt Cdr Pippa Bennett, for her massive contribution to the clinical phase of this 
work, her generosity in proof-reading this thesis and her tolerance of my laissez-faire 




Dr Joseph ‘Josh’ Wenke, for inspiring me and supervising my work at the US Army 
Institute of Surgical Research, and continuing to mentor and support me. His 
generosity with his time, impressive library of idioms, humour, and his friendship is 
































































































Academic endeavour, like surgery, is a collaborative effort and I would like to 
acknowledge the contribution of the following people to this work: 
 
Dr Joseph ‘Josh’ Wenke, for guiding me as I designed and conducted the animal 
studies which he co-authored. 
 
Kinton Armmer, Douglas S. Cortez, Heather A. Gooden, Alicia L. Lofgren, Alex 
V. Trevino and Dr James K. Aden of the Extremity Trauma Research Group, US 
Army Institute of Surgical Research who assisted in the animal husbandry, laboratory 
work and statistical analysis for the animal studies. 
 
Surg Capt Rory Rickard, for his assistance in co-authoring our analysis of combat 
tibia injuries. 
 
Surg Capt Mark Midwinter CBE (Rtd) for his assistance with the analysis of survival 
patterns which he co-authored.  
 
Dr Jon Bishop, for his sophisticated statistical skills which he applied to the analysis 
of combat survival in the work he co-authored. 
 
Surg Lt Cdr Pippa Bennett, for her contribution with the data collection in the 
analysis of the combat tibia injuries which she co-authored.  
 
Members of the Severe Lower Extremity Combat Trauma (SeLECT) study group: Gp 
Capt Jon Kendrew, Gp Capt Ian Sargeant OBE, Prof Sir Keith Porter KBE, Lt 
Col Tom Rowlands, Lt Col Al Mountain, and Dr Deb Mortiboy. Our discussions 
and their views and experience in managing those injured in combat over the last 14 
years helped shape the clinical studies in this thesis. 
 
Maj Henry Chandler and Maj Kirsty MacLeod who patiently hand-searched cases 










































































Chapter One: Introduction and review of the literature 
1.0 Introduction 1 
1.1 Combat Injury 2 
1.1.1     Trauma Registries  2 
1.1.2     Military Trauma Registries 3 
1.2 Combat limb injuries and their treatment 4 
1.2.1     Anatomic distribution of injuries 4 
1.2.2     Open Fractures and their Treatment  5 
1.3     Outstanding Questions 7 
1.3.1     Has survival after combat injury improved and are we     
measuring it accurately? 
7 
1.3.2     How common is infection after combat open fractures and 
what are the consequences? 
8 
1.3.3     How does the timing of surgical and antibiotic treatment of 
open fractures affect infection? 
9 
1.3.4     Are there novel treatments that might reduce infection in open 
fractures? 
9 
1.4 Conclusions 10 
1.5 References  10 
   
Chapter Two: Combat injury and survival 
2.0 Introduction 13 
2.1 Historic measures of combat survival 13 
2.1.1     Survival following a specific injury 14 
2.1.2     Case Fatality Rate 16 
2.2 Quantifying injury severity 17 
2.2.1     Anatomic measures of injury severity 17 
2.2.2     Anatomic/physiological measures of injury severity 18 
2.3 Measuring survival using an anatomic measure of injury severity 19 
2.3.1     Methods-data 20 
2.3.2     Methods-analysis 20 
2.3.3     Results 21 
2.4 Deriving an anatomic/physiological measure of combat injury 
severity 
23 
2.4.1     Deriving contemporary, combat relevant coefficients-Data set 24 
2.4.2     Deriving contemporary, combat relevant coefficients-Methods 25 
2.4.3     Deriving contemporary, combat relevant coefficients-results 26 
2.4.4     Measuring survival with revised coefficients-methods 28 
2.4.5     Measuring survival with new methodology-results 29 
2.5 Injury mechanism 30 
2.6 Anatomic injury patterns 31 
2.6.1     Have anatomic injury patterns changed?-Methods  32 
2.6.2     Have anatomic injury patterns changed?-Results 32 
2.7 Extremity injuries in survivors 35 
2.7.1     Characterising extremity injuries in survivors-methods 35 
2.7.2     Characterising extremity injuries in survivors-results 36 
2.8 Infections in open tibia fractures 41 
2.8.1     Determining the infection rate in open tibia fractures-Methods 42 
2.8.2 Determining the infection rate in open tibia fractures-Results 43 
2.8.3 Determining the consequences of infection 47 
2.9 Conclusion 47 
2.10 References 48 
	 x 
   
Chapter Three: Modelling open fractures 
3.0 Introduction 51 
3.1 Ethical and Legal Framework for animal research 51 
3.2 Model Selection 52 
3.3 Methodology of Contaminated Rat Femur Segmental Defect 54 
3.3.1     Surgical Procedure 54 
3.3.2     Outcomes measures 57 
3.3.3     Statistical Analysis 58 
3.4 Model Development 58 
3.5 Bacterial inoculation 60 
3.5.1     Bacterial inoculation-methods   60 
3.5.2     Bacterial inoculation-results 50 
3.6 Systemic antibiotics 63 
3.6.1     Systemic antibiotic regime-methods 63 
3.6.2     Systemic antibiotic regime-results 63 
3.7 Conclusions 66 
3.8 References 66 
   
Chapter Four: Timing of open fractures treatment 
4.0 Introduction 69 
4.1 Timing of Treatments: Methods 70 
4.1.1     Antibiotic Treatment 70 
4.1.2     Study Groups 71 
4.2 Results 71 
4.3 Conclusions 75 
4.4 References 75 
   
Chapter Five: Novel treatments of open fractures 
5.0 Introduction 77 
5.1 Irrigation with Chlorhexidine Solution Versus Saline 77 
5.1.1 Irrigation fluids: study groups and methods 78 
5.1.2 Irrigation Fluids: Results 79 
5.2 Local antibiotic gel versus antibiotic polymethylmethacrylate 
‘beads’ 
81 
5.2.1     Local Antibiotic Treatments 83 
5.2.2     Local Antibiotics-Study Groups and Methods 84 
5.2.3     Local Antibiotics: Results 85 
5.3 Local Bismuth thiol gels with systemic antibiotics 87 
5.3.1     Bismuth Thiols: Formulations 88 
5.3.2     Bismuth Thiols: Study Groups and Methods 89 
5.3.3     Bismuth Thiols: Results 90 
5.4 Conclusions 94 
5.5 References 94 
   
Chapter six: Discussion 
6.0 Introduction 97 
6.1 Has Survival After Combat Injury Improved and Are We 
Measuring it Accurately? 
97 
6.1.1     The Probability of Survival 98 
6.1.2     Using New Injury Severity Score to measure survival 99 
6.1.3     Developing Trauma Injury Severity Score coefficients to 101 
	 xi 
predict survival after contemporary combat injury 
6.1.4     Using contemporary Trauma Injury Severity Score coefficients 
to predict survival after contemporary combat injury 
104 
6.1.5     Future work in measuring survival after combat injury 105 
6.2 How common is infection after open combat fractures, and what 
are the consequences? 
106 
6.2.1     How common are open fractures after combat injury? 107 
6.2.2    How many combat injuries are complicated by infection? 107 
6.2.3    What are organisms are responsible for the infections? 109 
6.2.4    Is infection associated with a poorer outcome? 109 
6.3 How does the timing of surgical and antibiotic treatment of open 
fractures affect infection? 
111 
6.3.1     Model Development-Bacterial Inoculation 111 
6.3.2     Model Development-Systemic Antibiotics 111 
6.3.3     Model Development-Interpretation of results 112 
6.3.4     Model Strengths and Weaknesses 114 
6.3.5     The timing of surgical and antibiotic treatment of open 
fractures 
115 
6.4 Are there novel treatments that might reduce infection in open 
fractures? 
119 
6.4.1     Irrigation with Chlorhexidine Solution Versus Saline 119 
6.4.2     Local antibiotic gel versus antibiotic polymethylmethacrylate 
‘beads’ 
122 
6.4.3     Local Bismuth thiol gels with systemic antibiotics 126 
6.5 Conclusion 128 
   
   















































































List of Figures and Tables 
 
Tables 
1.1 Anatomic distribution of injures in historic conflicts. 5 
2.1 Number of fatalities and injured survivors per year. 21 
2.2 Output from the NISS model 22 
2.3 Details of the UK combat casualties used to determine military 
relevant Trauma and Injury Severity Score (TRISS) coefficients. 
25 
2.4 New Trauma and Injury Severity Score (TRISS) coefficients 26 
2.5 The performance of the new Gunshot Wound (GSW) and Blast 
Trauma and Injury Severity Score (TRISS) models. 
26 
2.6 Injured regions as defined by AIS system 33 
2.7 Predicted proportions of injuries for each body region by year.   35 
2.8 Incidence of extremity injury, long bone fracture and major 
amputation per calendar year of conflict with Population year at 
risk (PYAR) shown. 
37 
2.9 Mechanism of injury. 39 
2.10 Patterns of amputation. 39 
2.11 Bone loss grading system 43 
2.12 Definitive fracture fixation techniques. 43 
2.13 Causative microorganisms in the 22 cases requiring surgical 
treatment of infection. 
44 
3.1 Quantification of bacteria recovered from animals 14 days after 
inoculation with various quantities of bacteria, given in colony 
forming units (CFUs). 
62 
3.2 Quantification of bacteria recovered from animals 14 days after 
inoculation with 1 × 105 colony-forming units (CFUs) of S. aureus 
and treatment with various doses of systemic cephazolin for 72 
hours. 
65 
4.1 Metric showing the treatment timing combination of the seven 
study groups 
71 
4.2 Metric table showing p-values of direct comparisons between 
treatment groups according to Mann-Whitney analysis of the 
presence of the quantification of bacteria from recovered 
samples. 
74 
4.3 Statistical differences between treatment groups according to 
Fisher’s exact test comparing presence of bacteria. 
 
74 
5.1 Study groups detailing irrigation fluids used following surgical 
debridement six hours after initial injury and contamination with 
1x102 CFU of S. aureus. CHG: chlorhexidine 
 
79 
5.2 The similarity of the effect of various concentrations of CHG on 
the rate of detectable bacteria compared with control group. 
80 
5.3 Study groups detailing different treatments and quantity of 
antibiotic received by each group. 
84 
5.4 P-value for comparison of groups by quantitative cultures of 
recovered bacteria from bone and implant samples. 
86 




























































2.1 Plot of predicted probability of survival by NISS value for each 
year of study.  
22 
2.2 NISS values associated with a predicted 50% or greater 
probability of survival. 
23 
2.3 Flow diagram showing study recruitment and exclusion of 
casualties documented within the UK military Joint Theatre 
Trauma Registry (JTTR). 
24 
2.4 Receiver Operator Characteristic curve for the updated (GSW) 
and original TRISS models. 
27 
2.5 Receiver Operator Characteristic curve for the updated (blast) 
and original TRISS model. 
28 
2.6 TRISS associated with a 50% chance of survival by calendar 
year 
30 
2.7 The relative proportion of injuries caused by gunshot wounds 
(GSW) or blast (explosive munitions) 
31 
2.8 Distribution of head, face and neck injuries over time as 
proportion of total injuries. 
33 
2.9 Distribution of upper and lower extremity injuries over time as 
proportion of total injuries. 
34 
2.10 Survivors with extremity injury sustained per Population Year at 
Risk (PYAR), per year. 
38 
2.11 Schematic showing anatomic distribution of closed and open 
fractures. 
38 
2.12 Schematic showing level of amputation. 40 
2.13 Scatter plot showing length of hospital stay for patients with 
open versus closed long bone fractures. 
41 
2.14 Scatter plot showing the New Injury Severity Score by infected 
and un-infected groups. 
45 
2.15 Bar chart showing bone loss and infection. 46 
3.1 A microradiograph showing a proximally disarticulated rodent 
femur with 6mm segmental defect. 
55 
3.2 A limited spectrum photograph of a Kirby–Bauer antibiotic 
sensitivity test of the Xenogen-36 photon-emitting strain of S. 
aureus used in this model. 
56 
3.3 Proportion of samples with detectible bacteria in each group of 
10 animals 14 days after inoculation with various quantities of 
bacteria, given in colony-forming units. 
61 
3.4 Quantification of bacteria recovered from animals (10 per group) 
14 days after inoculation with various quantities of bacteria, 
given in colony-forming units. 
62 
3.5 Proportion of samples with detectible bacteria in each group of 
six animals 14 days after inoculation with 1 × 105 CFU of S. 
aureus and treatment with various doses of systemic cephazolin 
for 72 hours. 
64 
3.6 Quantification of bacteria recovered from animals 14 days after 
inoculation with 1 × 105 CFU of S. aureus and treatment with 
various doses of systemic cephazolin for 72 hours. 
65 
4.1 Mean bacterial quantification results of varying treatment timings 
with statistical groupings by combined bone and hardware 
results.   
72 
4.2 Proportion of samples from each treatment group with detectible 73 
	 xvi 
bacteria 
5.1 Proportion of bone and hardware samples with detectible 
bacteria from each group of ten animals 14 days after 
inoculation with 1x102 CFUs of S. aureus and irrigation with 
various fluids or combinations. 
80 
5.2 Mean bacterial quantification of bone and hardware samples 14 
days after inoculation with 1x102 CFUs of S. aureus and 
irrigation with various fluids or combinations. 
81 
5.3 Proportion of 20 samples from each treatment group of 10-
animals with detectible bacteria at 14 days. 
85 
5.4 Mean quantity of bacteria recovered from bone and implants 
from different treatment groups of ten animals. 
87 
5.5 Phase 1 results showing the proportion of 20 samples from each 
treatment group of ten animals with detectible bacteria at 14 
days after treatment with three different BT formulations with 
and without cephazolin. 
91 
5.6 Phase 1 results showing mean bacterial quantification results 
from each treatment group of 10-animals treated with three 
different BT formulations with and without cephazolin 
92 
5.7 Phase 2 results showing the proportion of sample types from 
each treatment group of ten animals treated with reducing doses 
of MB-8-2 combined with a cephazolin treatment. 
93 
5.8 Phase 2 results showing the proportion of sample types from 
each treatment group of 10 animals treated with reducing doses 
of MB-8-2 combined with a cephazolin treatment. 
93 
6.1 Article from Daily Telegraph 4th June 2015 regarding the 
publication of the NISS survival analysis earlier that year in the 
Journal of Trauma. 
100 
6.2 Idealised curve representing the ‘tipping point’, at which a host’s 




Chapter One:   Introduction 
 
1.0 Introduction 
The assertion that medical advances are one of the few benefits of war is often 
repeated1,2. There is a logic to this idea: armed conflicts typically injure large 
numbers of previously fit young people in a concentrated place and time and the 
society to which they belong have an instinctive desire to provide optimal care for 
them. This results in both incentive and opportunity for improvements in trauma care 
to be developed. 
 
The United Kingdom was continuously involved in over a decade of conflict, from the 
invasion of Iraq on 19th March 2003 to the cessation of combat operations in 
Afghanistan on the 27th October 2014. During this time all injured service personnel 
were evacuated to a single medical facility at the Royal Centre for Defence Medicine, 
Birmingham, UK.  
 
As the design of body armour3,4 and advances in resuscitation techniques5,6 evolved 
throughout the 12 years of conflict, it was speculated that casualties were surviving 
who previously would have succumbed to their injuries. As a result, it was asserted 
that surgeons were faced with survivors with injuries of a severity not previously 
encountered. In effect, morbidity had been increased as a result of the reduction in 
mortality. The greatest recovery and rehabilitation for these injured survivors, 
requires their wounds to heal free from infection6.  
 
In this chapter, I will outline how trauma registries allow the study of injury patterns 
across a large number of patients, and how these are implemented in the military 
context. I will then discuss the nature and character of combat injuries and explain 
the rationale for focusing research on extremity injuries and infection. 
 
Overall, this thesis seeks to characterise the combat injuries and define the burden of 
extremity injuries particularly open fractures complicated by infection. Furthermore, 





1.1 Combat Injury   
Unlike most traumatic injuries in peacetime, those sustained in combat are a result of 
a deliberate application of technology that aims to injure or kill. This is achieved by 
the transfer of energy from chemical form i.e. explosives or propellants, to the kinetic 
energy of bullets and blast fragments after detonation7. This kinetic energy is the 
ability to do work, in this case work equates to the shearing and laceration of body 
tissues when the kinetic energy is transferred into the tissues.  
 
 
1.1.1  Trauma Registries 
In addition to this heterogeneous pattern of injuries seen in trauma, the typical 
treatment pathway of a trauma casualty adds a further layer of complexity. Multiple 
healthcare professionals deliver care at numerous stages as the patient transitions 
from the prehospital environment, through the emergency department to the 
operating theatre and finally to critical care. As a result of these factors, determining 
the outcomes of patients across this complex system is challenging. 
 
In the 1960s the United States’ Academy of Sciences recognised that trauma care in 
the US was poor and recommended the improved collection of statistics as a basis 
for improving treatment8. As a result of this, the first trauma registry was established 
in Chicago in 19699. The stated aims of this registry were: 
 
 (1) to facilitate and improve patient care by rapidly locating and accurately 
 reproducing significant amounts of clinical information germane to the patient's 
 present clinical problem;  
 (2) to provide on-line clinical summaries of diagnostic and therapeutic 
 methods; 
 (3) to establish a data source for developing at-risk factors for accidental 
 events; 
 (4) to define the variables on which patient morbidity and mortality depend; 
 (5) to determine logistical and manpower requirements for a given 
 community's trauma needs;  
 (6) to estimate cost expenditures for certain injuries and their 
 comprehensive care requirements; 
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 (7) to provide continuous monitoring of project planning for the care of the 
 critically injured. 
 
Other cities and states developed similar registries and in the 1980s the American 
College of Surgeons initiated the Major Trauma Outcome Study, which led to the 
amalgamation and standardisation of local registries into the US National Trauma 
Data Bank (NTDB)10.  
 
Parallel to the US efforts to improve patient outcomes after trauma, in the UK in 1988 
Sir Miles Irving published his analysis of 1,000 trauma deaths and highlighted the 
inadequacies in British trauma care11. This led to the establishment of the UK’s own 
trauma registry, the Trauma Audit Research Network (TARN).  
 
 
1.1.2 Military Trauma Registries 
Collection of statistics on the sick and injured in the military has pre-dated efforts in 
the civilian setting. In 1780, Sir Gilbert Blane, Royal Navy physician to the West 
Indies squadron, insisted on monthly reports from all the Ships’ surgeons on the 
health and mortality of their crews12. Similar efforts to collect information on, and 
effect improvements in, casualty care have occurred in nearly all major conflicts 
since.  
 
In the UK, the Hostile Action Casualty Survey was developed in the Northern Ireland 
conflict in the 1970s, predominantly to examine the mechanisms and patterns of 
wounding and the efficacy of body armour13. Even though it was not designed for this 
purpose, HACS was sufficiently detailed to allow analysis of the performance of the 
combat casualty care system in the Falklands war.  
 
The first recognisably modern military trauma registry was set up by Brigadier Tim 
Hodgetts in 1999 during UK peace-keeping operations in Kosovo14. This registry was 
designed specifically to measure combat casualty care and was used as the basis for 
the UK’s Joint Theatre Trauma Registry (JTTR) for operations in the 2000s15. It 
differed from previous compilations of injury statisics and was a modern trauma 
registry in the sense that it contained integral statistical tools in order to measure the 
performance of the trauma system. 
	 4 
 
The JTTR was in place in an embryonic form for the start of combat operations in 
Afghanistan in 2001 and was fully functioning for the invasion of Iraq16 in 2003. Data 
is prospectively captured on all trauma cases admitted to deployed UK military 
medical facilities that trigger a ‘trauma alert’, or that are subsequently repatriated to 
the UK for treatment of their injuries. This data collection is performed by two sets of 
trained ‘Trauma Nurse Coordinators’ (TNCs): one team of TNCs is in the deployed 
Medical Treatment Facility (MTF) and the other is based back in the Royal Centre for 
Defence Medicine (RCDM) in the UK. The database is administered by UK Defence 
Statistics (UKDS) agency. 
 
The TNCs collect data on patient demographics and mechanism of injury, along with 
anatomic coding of injuries as per the Abbreviated Injury Scale (AIS) described in 
detail below, and physiological data i.e. vital signs and conscious level. The JTTR 
was established by the Academic Department of Military Emergency Medicine 
(ADMEM): as such, treatment details are focused on resuscitation e.g. blood 
products and the use of haemostatic dressings. Details on reconstructive surgery are 
not captured. Similarly, the only outcome recorded is mortality: there is no capture of 
patient reported outcomes, retention in military service, subsequent completion of 
military fitness test or any other measure of recovery. 
 
1.2 Combat limb injuries and their treatment 
As stated previously, injuries sustained in combat differ to those sustained in a 
civilian setting. Battlefield mechanisms of injury include explosions and high-energy 
gunshot wounds that are rarely encountered in the civilian setting. Unlike civilians, 
service personnel are normally wearing body armour when they are injured, 
potentially changing the distribution of their injuries. 
 
1.2.1 Anatomic Distribution of Injuries 
In conflicts since the Second World War, the majority of wounds sustained in combat 






 Falklands 17  US-Vietnam 18 US-Korea 19 
Extremity 
wounds 
75% 61% 65% 
n 233 17,726 111,716 
Table 1.1: anatomic distribution of injures in historic conflicts. 
 
The clear preponderance of wounds affecting the extremities is demonstrated in 
these reports from previous conflicts. However, it is not possible to ascertain if these 
historical reports involve all casualties or only survivors. Similarly it is not clear how 
many of these wounds involved open fractures, nor what infection rates were. 
 
Given the focus on improving body armour for the head and torso in the recent 
conflicts20,21, it is reasonable to speculate that the proportion of injuries affecting the 
limbs will be greater compared to previous conflicts since the Second World War. If 
this assumption is correct, then the trend is likely to continue since personal 
protection continues to improve22,23. Therefore, improving the ability to treat and 





1.2.2 Open Fractures and their Treatment 
Combat wounds do not occur in sterile, controlled surroundings and are universally 
contaminated. The extent of this contamination varies, and depends on multiple 
factors including the clothing the casualty was wearing, the environment in which 
they were operating, and the nature of the munitions that injured them. 
 
Infection after combat injury has been a focus of significant attention since the birth of 
modern surgery in the 17th and 18th centuries. Key figures in the development of the 
discipline, Hunter and Pare-both experienced military surgeons, wrote extensively of 
the difficulties and dangers of wound infection 24,25.  In the First World War, fought 
largely in the heavily manured agricultural fields of Belgium and France, the wound 
infection incidence and aggression surprised military surgeons26. 
 
A fracture is a disruption in the continuity of a bone’s macroscopic structure: it is 
classed as ‘open’ where there is a breach in the skin and soft tissue envelope 
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overlying the fracture. The preponderance of combat wounds to affect the extremities 
is clear, and given the high-energy mechanisms causing these injuries, it is not 
surprising that extremity injuries from the modern battlefield commonly result in 
fractured bones.  
 
A study by the Owens et al. examined 1,566 US military casualties wounded or killed 
in the period from 2001 to 2005 as a result of enemy action. Their findings revealed 
that 26% of extremity wounds involved fractures, of which 82% were open27. This 
study was based on the earliest form of the US JTTR which was not regarded as 
highly reliable28. The US JTTR at that time used 9th edition of the International 
Classification of Disease (ICD-9) published in 1978 rather than trauma specific 
classifications systems like the Abbreviated Injury Scale (AIS)29 more commonly 
used by Trauma Registries. 
 
In an open fracture, there is a communication between the fracture and the external 
environment, leading to inevitable microbial contamination of exposed, injured bone 
tissue. The main difference between open and closed fractures is the increased risk 
of infection due to this contamination. While it is accepted that some wound 
infections are caused by fungal pathogens, this is relatively rare compared to 
bacterial infection which is therefore the focus of this work30. 
 
The current treatment of open fractures is aimed at preventing infection through two 
means: removal of contamination and necrotic tissue, and optimisation of the host 
immune system to eradicate pathological microbes.  
 
The removal of contaminated and necrotic tissue is usually performed as part of a 
surgical procedure with two components. Firstly, the surgeon identifies and removes 
necrotic tissue and any frank contamination in a process known as excision or 
debridement. Secondly, irrigation is performed, whereby a liquid is used to rinse both 
macroscopic and microscopic contamination from the wound31. 
 
The relationship between the timing of surgical and antibiotic treatment of open 
fractures is not understood. It has been established that bacteria are capable of 
exponential growth in wounds32 and therefore it is reasonable to assume that the 
earlier that either treatment is initiated then the lower the infection rate will be. 
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However, proving this via a clinical trial would be un-ethical and to date animal 
research in this area has looked at the antibiotic and surgical treatments separately 
and so the relationship between the two treatments is not understood.  
 
Optimising the host immune system’s ability to eradicate pathological bacteria from 
an open fracture wound is multifactorial and not fully understood. The use of 
systemically administered antibiotics to create an environment within the wound bed 
where contaminating bacteria are unable to thrive reduces infection33. Furthermore it 
has been shown that increased stability in a fracture, and therefore the wound bed, 
reduces infection in an animal model 34. Swelling in an enclosed or partially enclosed 
muscular compartment can compromise blood flow and cause further necrosis, a 
process prevented by surgical decompression or release of surrounding fascial 
tissue. 
 
The reason that musculoskeletal infection can be resilient to antibiotics is 
increasingly understood to be due to the ability of some bacteria to form biofilm35. In 
basic terms this is the process by which bacteria adhere to a surface, secrete a 
‘slime’ of hydrated polymeric matrix and then enter a dormant state36. This then 
allows the bacteria to resist antibiotic concentrations in orders of magnitude greater 
than would be toxic in their planktonic form.37 
 
1.3 Outstanding Questions 
This thesis will attempt to improve the knowledge and understanding of combat 
injuries, in particular those involving open fractures of the limbs, by concentrating on 
a number of outstanding questions:  
 
1.3.1 Has survival after combat injury improved and are we  measuring it 
accurately? 
British military forces were on engaged in conflict for 12-years between the invasion 
of Iraq on the 19th March 2003 until the end of combat operations in Afghanistan on 
27th October 2014. Over the course of this period, it was asserted that combat 
casualty care system performance had improved significantly, resulting in larger 
numbers of seriously injured casualties requiring complex medical care and 
rehabilitation38. This situation can be summarised as a lowering in mortality after 
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combat trauma has resulted in a rise in morbidity as casualties were surviving with 
injuries that would have been fatal in the early stages of the conflicts. 
 
However, even confident assertions to this effect by the National Audit Office were 
followed by the admission that accurately quantifying survival improvement is 
extremely challenging38. Previously, no academic study examining survival in UK 
service personnel have been published, nor official statistics released that allow such 
assertions to be examined. Whereas organisations like the UK TARN and the US 
NTDB provide external oversight of respective hospital’s performance in terms of 
survival after injury, the UK DMS is largely responsible for monitoring its own 
performance, it is therefore important to clearly demonstrate that its performance is 
measured as accurately as possible. 
 
It is unclear how common extremity wounds were in the recent conflicts and whether 
they frequently involved open fractures. 
 
This thesis will seek to determine whether survival after combat injury has improved 
over the duration of the conflicts in Iraq and Afghanistan 2003-2014, and examine the 
best way to measure this improvement. Furthermore, whether this survival 
improvement has resulted in large numbers of surviving casualties with open 
fractures will be established. 
 
 
1.3.2 How common is infection after open combat fractures, and what are the 
consequences? 
Combat open fracture wounds are assumed to be universally contaminated, however 
in the antibiotic era it is not clear how common wound infections are, nor how serious 
are their consequences are. It is possible that this is no longer a common or serious 
problem. 
 
This thesis will determine the infection rate after combat open fracture, identify 
causative pathogens and establish the consequences of infection on fracture healing 




1.3.3 How does the timing of surgical and antibiotic treatment of open fractures 
affect infection? 
It is possible that early administration of systemic antibiotics might mitigate the effect 
of delaying surgery. However, if the is not the case, then there are implications for 
military medical logistics since casualties with open fractures will require transport 
across the battle space to receive surgical treatment without delay in order to avoid 
higher infection rates. 
 
This work will attempt to explore the relationship and effect of timing of surgical and 
antibiotic treatment on infection in open fractures.  
 
 
1.3.4 Are there novel treatments that might reduce infection in open fractures? 
The last development in the prevention of infection in open fractures was the routine 
use of antibiotics for prophylaxis. There have since been three areas where novel 
treatments with the potential to reduce infection rates might emerge: 
 
 A. Since Lister first described irrigating open fractures with Carbolic  acid in 
186739, various antiseptic chemicals have been assessed for their ability to 
reduce infection in open fracture wounds but none have been shown to be 
superior to saline40. Chlorhexadine however is a relatively new antiseptic41 
which is frequently used clinically as it is toxic to micro-organisms while being 
relatively benign to mammalian tissue42. Chlorhexadine has not be evaluated 
as a potential irrigation solution for open fractures either clinically or in an 
 animal model. If this readily available solution is superior to saline as a wound 
irrigation fluid at reducing infection in open fractures then this would provide a 
simple way for clinicians to reduce infection rates. 
 
 B. For antibiotics to be effective they have to reach a concentration in the 
 wound sufficient to be toxic to the bacteria present there. If they are  
administered systemically e.g. intravenously or orally, in order for them to be 
effective their concentration throughout the body, not just the wound, must 
exceed this threshold. Not only is this inefficient, but it risks unintended 
adverse systemic effects. Administering antibiotics locally and directly to the 
wound could potentially avoid systemic side effects while achieving greater 
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concentrations in the wound. Identification of an effective vehicle for delivering 
local antibiotics into open fracture wounds could improve the efficacy against 
pathological bacteria in wounds while avoiding systemic toxicity.  
 
C. The behaviour of bacteria in forming biofilm and the role this plays in 
resilience to antibiotics and therefore the development of recalcitrant 
musculoskeletal infection is increasingly understood35. Treatments that 
address this defensive bacterial behaviour therefore have the potential to 




This thesis will define the nature of combat injuries from the recent conflicts in Iraq 
and Afghanistan. The question of whether survival has improved over the period of 
the conflict will be examined. Furthermore, the rate and consequences of open 
fracture infection will be determined.  
 
An animal model of contaminated open fractures will be used to improve the 
understanding of the relationship between the timing of treatment and infection and 
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Chapter Two:  Combat injury and survival  
 
2.0 Introduction 
Death in combat is an unambiguous metric and was used historically to measure the 
human ‘cost’ of war.1 However mortality is only part of the human cost, as examining 
death rates ignores those who survive with combat injuries. It has been argued that 
over the last two centuries, with the emergence and application to war of modern 
medicine, survival after combat injury has improved.2  
 
If this assertion is correct then survivors with combat injuries will increasingly present 
a relatively larger need for medical and rehabilitative care. As such, improvements in 
the understanding and treatment of combat injuries will have even greater potential 
benefit for those surviving with combat injuries. 
 
The assumption that survival following combat injury has improved over the last two 
centuries has inherent logic given the medical advances over such a long period. 
However, demonstrating a significant improvement over the twelve years that the UK 
was involved in major combat operations in Iraq and Afghanistan is more 
challenging.  
 
In order to plan the surgical and rehabilitative care of those injured in combat, it is 
important to understand the nature of the injuries that casualties are surviving with. 
This thesis concerns the field of orthopaedic trauma and will therefore be limited to 
examining injuries to the limbs and pelvis that are managed by this surgical 
speciality. 
 
2.1 Historic measurements of combat survival 
As stated previously, it is reasonable to assume that over the last two centuries 
survival after combat injury has improved. There are two possible methods for testing 
this assumption: firstly by examining the mortality from a specific injury type in 
different conflicts over history; and secondly, by looking at the ratio of those killed to 





2.1.1 Survival following a specific injury 
This is the simplest method for measuring changes in survival after combat injury. It 
involves establishing the mortality rate in a sample of casualties with a similar injury 
type and in a specific conflict or time period. This is then compared with the mortality 
rate in a cohort from a different conflict or time period but with the same injury.   
 
This methodology relies on two assumptions: firstly that all types of a specific injury 
are of the same severity, e.g. a 1915 German Imperial Army bullet traversing an 
abdomen will produce similar wounds to a 2008 AK-47 bullet fired by an Afghani 
insurgent. 
 
The second assumption is that survival from that particular injury type is a valid 
surrogate of survival from all other injury types, e.g. improvements in survival 
following a head injury develop at the same pace as those following abdominal injury. 
 
An obvious example of this metric is the open femur fracture, which was an area of 
considerable focus in the First World War. In his book on surgical care in the First 
World War The early treatment of war wounds, the Royal Army Medical Corps 
surgeon Sir Henry Grey stated that in the first two years of the war, mortality from a 
gunshot wound causing an open femur fracture was 80%3. This is consistent with the 
account of James McBean Ross MC, a doctor serving with a Royal Marine Battalion 
in the First World War:  
 
“It is an exceedingly common impression amongst both officers and men that a 
compound fracture of the upper half of the femur is necessarily fatal. My experience, 
perhaps unfortunate, is that a very large number of such cases die of shock, either at 
the regimental aid post, the field ambulance or the casualty clearing station.”4 
 
Assuming then that an open femur fracture resulting from a gunshot wound had a 
high mortality in the First World War, how does this compare with mortality from 
similar injuries today? 
 
To answer this question, I used data from the Joint Theatre Trauma Registry (JTTR). 
As described in chapter one, the JTTR is an electronic database that prospectively 
gathers data on casualties sustained overseas and is administered by Defence 
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Statistics. Data are gathered on all casualties either killed immediately or who are 
injured and trigger a trauma alert on arrival at a deployed medical facility, or those 
whose injuries subsequently require repatriation to the UK. The data is collected by 
research nurses at deployed medical facilities and at the Royal Centre for Defence 
Medicine (RCDM), Birmingham, United Kingdom5. Research nurses use the 
Abbreviated Injury Scale (AIS) anatomic injury system to classify all injuries.6 
 
Approval to search this JTTR was granted after formal application to the Joint 
Medical Command under number RCDM/Res/Audit/1036/14/0427. 
 
The registry was searched for AIS codes that described bony injuries of the hip, 
femur or knee sustained between the invasion of Iraq on 19 March 2003 and 31 
December 2012. There were no records of fatality cases with an isolated open femur 
fracture in that period. Conversely there were 48 open femoral shaft fractures 
amongst survivors, half of which (25/48) were as a result of gunshot injury 7. 
 
Using this methodology, I was able to demonstrate a clear difference in survival 
between the early years of the First World War and the recent conflicts a century 
later. The same injury in the earlier conflict was associated with a high likelihood of 
fatality, whereas in the recent conflicts all patients survived this type of injury. 
 
Despite its illustrative utility, this example also demonstrates the weaknesses 
inherent in this methodology. First, there is heterogeneity within this injury type: there 
is clearly a difference in injury severity between an open fracture from a gunshot 
wound where the femoral artery is severed and one where it is not, however such 
distinction is not made with this methodology.  
 
The second weakness is the assumption that the mechanism of injury in the First 
World War and the recent conflicts are the same: this assumption is unlikely to be 
valid. Weapons used by the Imperial German Army were different to those used by 
insurgents in Iraq and Afghanistan, and therefore there will invariably be differences 
in the injuries that these weapons caused. Similarly, the wounds produced by artillery 
shells and those by buried improvised explosive devices are likely to be different.    
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However, perhaps the most important weakness in this methodology is the 
questionable validity of extrapolating improvements in survival from this one type of 
injury across all combat trauma. Specifically, open femur fractures were subject to 
particular attention in the First World War in an attempt to reduce mortality. 
Considerable efforts were made to train and equip medics to apply Thomas splints 
and dressings to open femur fractures and rapidly extricate injured patients8. 
Therefore survival from this injury is likely to have improved faster than other combat 
injuries. 
 
Though measuring survival after a specific injury can indicate trends in survival it is 
very limited in its ability to accurately measure improvements in survival after combat 
injury. Furthermore, although it has the advantage of being applicable in a context of 
limited casualty statistics, it is unlikely to be sensitive to subtle changes. 
 
2.1.2 Case Fatality Rate 
The ratio between the number of fatalities from a conflict and the overall number of 
casualties (survivors and fatalities) is known as the Case Fatality Rate (CFR). This 
methodology has the advantage of relying on very simple casualty statistics, which 
are available even from conflicts in the 19th Century: this allows CFRs from different 
conflicts to be compared. 
 
Using the CFR to compare survival rates from different conflicts relies on a number of 
assumptions. Firstly, the CFR is a ratio with a numerator and denominator; the 
numerator is the number of military battlefield fatalities, which is clearly defined and, 
at least in modern conflicts, unambiguous and meticulously recorded. The definition 
of the denominator i.e. the total number of casualties, is more complicated as there is 
ambiguity about what constitutes a wounded casualty i.e. an injured survivor, 
specifically, what severity of injury qualifies as ‘wounded’. Multiple different definitions 
have been used throughout history, with terminology varying not only between 
conflicts, but between militaries for the same conflict. 
 
Comparisons of the CFR between different conflicts, or over the course of long 
conflicts, rely on the assumption that the injury profiles are the same with an identical 
distribution of injury severity. This is hard to quantify but seems highly unlikely. For 
example, if a conflict involved more weapons designed to wound rather than kill e.g. 
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anti-personnel mines, then the CFR would appear lower than if a greater number of 
lethal weapons were used. 
 
Despite these confounders, the CFR was used by the US military to justify their 
assertion that survival after combat wounding improved over the course of their 
involvement in the wars of Iraq and Afghnistan9.  
 
 
2.2 Quantifying injury severity 
Traumatic injuries are heterogeneous, in order to allow valid analysis, injuries need to 
quantified. 
  
2.2.1  Anatomic measures of injury severity  
As previously stated, traumatic injuries are heterogeneous and confound attempts to 
correlate, cohort and analyse patterns of wounding. In the 1960s the American 
Association of Automotive Medicine (AAAM) devised a system for quantifying injury 
severity based on the anatomic nature of the injury. The AAAM intended to use the 
score to allow the correlation of specific injuries with collision types, and measure the 
injury severity associated with certain car designs. 
 
Subsequently known as the Abbreviated Injury Scale (AIS), this system divides the 
body into eight anatomic regions i.e. lower limbs, upper limbs, head, face, neck, 
thorax, abdomen and spine, and then assigns a numerical code from one to six to 
each specific injury based on the threat to life from that injury. A score of one is minor 
and six is regarded as untreatable and unsurvivable. This system allowed the overall 
injury burden to be calculated for both individual regions and the whole casualty: 
patients with similar overall injury burdens could be grouped, even if their actual 
injuries were different10. Since 1969 the AIS has been expanded and refined 
periodically by the AAAM11-14 with the most recent version published in 20156. 
 
The AIS was used as the basis of an anatomic measure of injury severity by the 
Injury Severity Score (ISS), developed by Prof. Susan Baker in the 1970s using 
hospital and coroner’s data from Boston in 1968-915. The ISS used a simple 
methodology: the highest AIS values from the three most severely injured regions 
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were squared and summed, with the resultant score capped at 75. In their original 
series, no patient survived with an ISS of greater than 50. 
 
The use of only a single worst AIS score from an individual anatomic region was 
recognised as an arbitrary feature of ISS and a potential flaw. In practice this meant 
that a double lower limb amputee was regarded as having the same lower limb injury 
burden as a single lower limb amputee. This was resolved with the New Injury 
Severity Score (NISS), which refines the original methodology by summing the 
squares of the three highest AIS values, even if they occur in the same region16. 
 
2.2.2 Anatomic/physiological measures of injury severity  
The obvious criticism of the purely anatomic measure of injury severity was that is 
does not take into account a patient’s physiological response to the traumatic insult. 
To address this, in the 1980s Champion and colleagues17,18 proposed the Trauma 
Score (TS), and then the Revised Trauma Score (RTS), as physiological measures 
of injury severity. This approach used conscious level, along with cardiac and 
respiratory observations, to quantify physiological derangement in an attempt to 
predict death after injury. 
 
Inevitability a system developed that used both anatomic scores and physiological 
parameters combined into a single trauma severity scale, and in the early 1980s the 
Trauma Injury Severity Score (TRISS) evolved19-21.  
 
TRISS not only combined anatomic scores of injury severity with a measure of 
physiological derangement, but also included the patient’s age and whether they 
were injured by a blunt (e.g. motor vehicle collision or fall) or penetrating (e.g. 
stabbing or shooting) mechanism. 
 
The TRISS methodology uses weighted co-efficients which were based on data from 
the Major Trauma Outcome Study (MTOS) established in 1982 and running to 
198722. These coefficients allowed for the probability of survival (PS) to be 
calculated. It was the intention of those who developed TRISS that: ‘As 
improvements in trauma care over time result in decreased mortality, these MTOS 
coefficients can be expected to change’. 
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The PS following an injury is calculated using the following TRISS equation: 
 
𝑃𝑆 = 1 (1 + 𝑒!!) 
 
Where β = b0 + bISS + bAge + bGCS + bRR + bSBP 
 
ISS: Injury Severity Scale, GCS: Glasgow Coma Scale, RR: Respiratory Rate, SBP: Systolic Blood 
Pressure. The weighting of the coefficients ‘b’ vary depending on whether the mechanism of injury 
was blunt or penetrating. 
 
 
The use of PS allowed trauma systems to be evaluated and compared: if a patient 
dies but their PS is >0.5 they are an unexpected fatality. Similarly, if a patient lived 
despite a PS <0.5 they are an unexpected survivor. A well performing trauma system 
would have more unexpected survivors than unexpected fatalities. 
 
TRISS is the most widely adopted methodology to measure trauma system 
performance and is used by the US NTDB23, the US military trauma registry24 and 
the UK JTTR25. 
 
2.3 Measuring survival using an anatomic measure of injury severity 
In order to test the assertion that survival following combat injury has improved over 
the course of the conflicts in Iraq and Afghanistan, I originally intended to use TRISS 
as a widely used, combined anatomic and physiological tool for predicting survival. 
However, during discussions with the UK JTTR and UK Defence Statistics it became 
apparent that the original TRISS coefficients based on 1980s US civilian data were 
being used. Furthermore it was not apparent if injuries from explosive weapons were 
being coded as penetrating or blunt. 
 
Therefore I decided to rely initially on the NISS figures from the UK JTTR to measure 
if survival had improved. I intended to revisit the TRISS methodology and revise the 
coefficients later to: a) accurately reflect the contemporary standard of care and b) 
develop a coefficient for the mechanism of explosive injury. 
 
It was apparent that due to the heterogeneous nature of the data, sophisticated 
modelling would be required to determine if the NISS predictive of survival increased 
over the study period. Therefore I requested the assistance of Dr Jon Bishop, a 
biostatistician from the University of Birmingham Clinical Trials unit, was engaged. Dr 
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Bishop developed the statistical modelling described below on the basis of the 
analytical questions framed for him.  
 
2.3.1 Methods: data 
The project was approved and registered with the Joint Medical Command 
RCDM/Res/Audit/1036/12/0319. The JTTR was searched for all UK casualties 
injured or killed in Iraq and Afghanistan between 2003 and 2012. New Injury Severity 
Scores were used as an anatomic measure of injury16.  
 
In order to provide a denominator to the casualty figures, population years at risk 
(PYAR) were calculated between 2008-12 from UK Defence Statistics data. This was 
based on computerised records of every day spent in either of the two operational 
theatres by each service person. These figures were summed for each calendar year 
and divided by 365 to give the PYAR i.e. the equivalent number of personnel 
deployed for 12 months. For 2003-7, detailed personnel records were not available: 
rather the information was extrapolated from Ministry of Defence (MoD) figures on 
troop levels contained in memoranda to the UK Parliament and is regarded as less 
precise26,27. All PYAR figures exclude Special Forces (SF), as details on SF 
deployments are not released by the MoD. 
 
2.3.2 Methods: analysis 
Data were grouped into calendar year cohorts according to the date of injury, and 
logistic regression used to examine relationships between year of injury and specific 
variables. In all models year of injury was coded as a continuous variable on the 
range 1-10 corresponding to years 2003-12.  
 
A model was developed where the NISS score was included as a continuous variable 
as both a main effect and as part of an interaction term with year of injury. The 
interaction between year of injury and NISS was statistically significant (p = 0.009). 
The year of injury was modelled using restricted cubic splines to allow for flexible 
relationships.  Model selection was based on Akaike Information Criterion28. Logistic 
regression was used for this analysis and fitting was performed using maximum 
likelihood estimation. The reference level of the outcome variable was coded as 
‘Fatality’ (vs. ‘Survival’).   
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The JTTR recorded 2,792 UK casualties injured or killed during service in Iraq and 
Afghanistan. The mean age was 25.7 years (SD=5.9) and 2,746 (98%) were male. 
The majority of casualties (2,227, 80%) were a result of hostile action, with the 
remaining 565 (20%) resulting from incidents not involving enemy forces e.g. road 
traffic collisions. There were 608 fatalities (22% of all casualties) during this decade. 
The distribution of casualties and fatalities throughout the 10-year study period is 
shown in Table 2.1.  
 
 
 Fatalities Injured Survivors PYAR CFR 
2003 50 43 17,820 54 
2004 23 47 10,483 33 
2005 24 76 10,767 24 
2006 68 109 13,000 38 
2007 88 320 13,300 22 
2008 55 214 13,513 20 
2009 109 435 11,909 20 
2010 104 418 11,657 20 
2011 46 301 11,771 13 
2012 41 221 11,488 16 
Total 608 2184 125,708 22 
 
Table 2.1: Number of fatalities and injured survivors per year. PYAR = personnel 
years at risk; CFR = case fatality rate expressed as a percentage. 
 
 
The odds of surviving a given injury severity was examined by analysing NISS as a 
continuous variable in a logistical regression model of NISS score and year, the 













Model 2   
NISS OR 95% CI 
10 1.67 (1.39, 2.00) 
25 1.55 (1.35, 1.77) 
50 1.36 (1.25, 1.49) 
75 1.20 (1.07, 1.36) 
Observations 2762 (Fatalities: 590) 
R2 0.830  
LR χ2 2121.81 Pr(>χ2)<0.0001 
 
Table 2.2: Output from the NISS model – Odds ratios (ORs) obtained from logistic 
regression of NISS score and Year (main effects and interaction) on survival.  ORs 
denote odds ratio of a unit change in year for a fixed NISS value (e.g. the odds ratio 
of survival increased by a factor of 1.67 per year for a casualty with a NISS of 10). 
 
 
Analysis demonstrated a consistent improvement in survival year-on-year over the 




Figure 2.1: Plot of predicted probability of survival by NISS value for each year of 
study. Shaded regions indicate the 95% confidence intervals for the predicted values 
obtained from the logistic regression model summarized in Table 2.2. 
 
 
The NISS model can be used to estimate the NISS value associated with a 50% 
probability of fatality for each year in the study period. The estimated probabilities of 
survival were obtained from the model for every possible NISS value in each year. 
The smallest NISS value with a corresponding 95% confidence interval lower limit 
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that exceeds 50% was identified in each year. This 50% survival NISS value rose 
from 32.5 in 2003 to 59.6 in 2012 (Figure 2.2). 
 
 
Figure 2.2: NISS values associated with a predicted 50% or greater probability of 
survival predicted by the logistic regression model summarized in Table 2.2. 
 
This analysis, using an anatomic measure of injury severity, indicates that over the 
10-years of the study period, survival improved significantly. 
 
 
2.4 Deriving an anatomic/physiological measure of combat injury severity 
As described in section 2.3, it was initially my intention to use TRISS to measure 
improvements in survival, as it has the advantage of being a combined anatomic and 
physiological method of measuring injury severity. However, as previously stated the 
version of TRISS the UK JTTR used was based on clinical outcomes from the 1980s 
and lacked a clear method for coding injuries from explosive mechanisms using 
either blast or penetrating coefficients. 
 
The aim of this part of the work was to adapt the TRISS coefficients in two ways. 
Firstly, to reflect the contemporary standard of military clinical care, and secondly to 
allow for mechanisms of injury relevant to the military, specifically explosive injury, to 
be accurately coded. 
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2.4.1  Deriving contemporary, combat relevant TRISS coefficients: data set 
This phase of work was approved by the Joint Medical Command as an extension to 
the previously described phase on survival using NISS (section 2.3.1). Due to the 
time taken to analyse the previous data set it was possible to expand the previously 
described 10 years of data to 12 years. 
 
The JTTR was searched for all UK Casualties injured or killed in Iraq and 
Afghanistan by explosive or gun-shot mechanisms between 1st Jan 2003 and 31 Dec 
2014. This calendar period encompassed the invasion of Iraq in  
19 March 2003 until the cessation of major combat operations in Afghanistan on the 
12th December 2014. 
 
There were 3,043 UK casualties identified within the JTTR in the study period: 622 
(20%) were injured by mechanisms other than explosive munitions or gunshot 
injuries, and were excluded. Of the 2,421 remaining cases, a further 319 (13%) were 
excluded due to inadequate data leaving a study population of 2,102 (Figure 2.3).  
 
 
Figure 2.3: Flow diagram showing study recruitment and exclusion of casualties 
documented within the UK military Joint Theatre Trauma Registry (JTTR) resulting in 




The study population contained 1,637 survivors and 465 fatalities; further details 
relating to the casualties can be found in Table 2.3. 
 
 
 Explosive Gun Shot 
Wound 
Total 
Survivors 1,163 474 1,637 
Fatalities 311 154 465 
Total 1,474 628 2,102 
    
Table 2.3: Details of the UK combat casualties used to determine military relevant 
Trauma and Injury Severity Score (TRISS) coefficients. 
 
 
2.4.2  Deriving contemporary, combat relevant coefficients: methods 
In order to perform this phase of study, again I requested Dr Bishop to develop 
another multivariable logistic regression model.  The variables were selected to 
mirror the construction of the original TRISS model21.  Each component of the 
Revised Trauma Score (RTS, described above in section 2.2.2) was included in the 
model as an independent predictor variable with a coded value between 0 and 4, as 
determined by the RTS thresholds.   
 
Age at injury is normally included in TRISS models as a binary variable (assigned 0 if 
age <55, 1 if age ≥55).  In our dataset fewer than five casualties were aged 55 or 
over at time of injury: therefore, we had insufficient data to estimate the parameter 
corresponding to age and excluded this variable from our model. 
 
The standard TRISS formula was used: 
  
𝑃𝑠 = 1 (1+ 𝑒!!) 
 
Where β = b0 + b1(ISS) + b2(GCSc) + b3(RRc) + b4(SBPc) and the c subscript denotes 
the use of the coded value (0 to 4) rather than the observed value.   
 
A variable corresponding to mechanism of injury (either gunshot or explosive) was 
then included and the parameters for each of these levels estimated. 
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Model accuracy was assessed by evaluating the area under the Receiver Operating 
Characteristic (ROC) curve, with reporting of the Area Under the Curve (AUC) and 




2.4.3  Deriving contemporary, combat relevant coefficients: results 










Variable    
TRISS 
coefficient 
α1 2.1361 -1.0996 
RR 
(breaths/min) 
βRR 0.2149 -0.1261 
SBP (mmHg) βSBP 1.0968 1.0761 
GCS βGCS 0.6818 1.1228 
ISS βISS -0.1053 -0.0490 
 
Table 2.4: New Trauma and Injury Severity Score (TRISS) coefficients derived from 
contemporary UK combat casualty data. 
 
 
If a predicted probability of survival (PS) of 0.5 or above is taken as denoting survival 
and a probability of less than 0.5 as denoting fatality, then the accuracy of the revised 









(TRISS GSW Model) 
Fatality Survived Fatality Survived 
Observed 
 Outcome 
Fatality 303 8 149 5 
Survived 16 1147 9 465 
 
Table 2.5: The performance of the new Gunshot Wound (GSW) and Blast Trauma 




Comparing the predictions from the GSW TRISS model to the observed outcomes, it 
demonstrates a sensitivity of 98.1% (465/474) and a specificity of 96.8% (149/154) 
giving an overall accuracy of 97.8%  (614/628). With respect to the explosive TRISS 
model, there is a sensitivity of 98.6% (1147/1163), a specificity of 97.4% (303/311), 
giving an overall accuracy of 98.4% (1450/1474).  
 
The ROC curve for the updated GSW TRISS model is shown in Figure 2.4 with a c-
statistic of 0.9966 (95%CI: 0.9940, 0.9992). The ROC for the explosive TRISS model 
is shown in Figure 2.5 with a c-statistic of 0.9979, (95%CI: 0.9966, 0.9991).   
 
Figure 2.4: Receiver Operator Characteristic (ROC) curve for the updated Gun-Shot 
Wound (GSW) Trauma and Injury Severity Score (TRISS) model (grey) compared to 





























Figure 2.5: Receiver Operator Characteristic (ROC) curve for the updated Blast 
Trauma and Injury Severity Score (TRISS) model (grey) compared to the original 
TRISS model (dotted)21. 
 
 
Global goodness-of-fit can be assessed through the le Cessie-Van-Houwelingen-
Copas-Hosmer test statistic, which gives a p-value of 0.799 for this model. This 
indicates there is no evidence that the available data was a poor fit for this model.  
 
Model calibration can be assessed through estimating the uniform shrinkage factor or 
optimism of the model33. Models that are well calibrated produce predicted 
probabilities that closely match observed probabilities and have calibration slopes 
close to 1. Following bootstrap resampling using 999 replicates, the revised TRISS 
model has a calibration slope of 0.9357, suggesting a high level of calibration with 
some small level of over-fitting.   
 
The overall accuracy of predictions can be assessed through the Brier score, which 
measures the average prediction error. In well-specified models a Brier score of 0 
denotes perfect prediction and a score of 0.25 denotes the worst possible 
performance.  The revised TRISS model has a Brier score of 0.014 suggesting a high 
level of predictive accuracy. 
 
2.4.4 Measuring survival with revised coefficients: methods 
The updated TRISS coefficients for both the explosive and gunshot models were 
used to calculate new TRISS values for casualties wounded by either mechanism of 
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injury.  These updated TRISS values were used in logistic regression analyses to 
model survival outcomes using the methodology previously described in section 
2.3.234. Data were grouped into calendar year cohorts according to date of injury and 
logistic regression was used to examine the relationship between year of injury and 
updated TRISS. TRISS was modelled as a continuous variable both a main effect 
and as part of an interaction term with year of injury. Year of injury was modelled 
using restricted cubic splines to allow for flexible relationships. Model selection was 
based on Akaike’s Information Criterion28 and fitting was performed using maximum 
likelihood estimation. 
 
All model analysis was conducted using R and the libraries: stats29, rms30, effects35 
and ggplot236.  
 
 
2.4.5 Measuring survival with new methodology: results 
The relationship between survival and time was examined by plotting the smallest 
TRISS value at which the lower limit of the 95% CI for the predicted probability of 
survival exceeded 0.5 in each year (Figure 2.6). With the original TRISS scoring 
system, the performance of combat casualty care appears to peak in 2009 and then 
decline slightly with calculations in 2013 and 2014 not marked as the lower 95%CI 
remains greater than 0.5. When the new explosive and GSW coefficients are used to 
model survival over the study period the improvement in survival is shown to ‘plateau’ 





Figure 2.6: TRISS associated with a 50% chance of survival by calendar year, as 
determined by logistic regression. Calculations based on original 1987 TRISS 
methodology for all casualties shown, along with modified TRISS values for separate 
groups of casualties injured by explosive or GSW mechanisms. The plot for the 




2.5 Injury mechanism 
The mechanism of injuries seen in combat is distinct from that seen in the civilian 
healthcare setting, but it is not homogenous and changes over time as the character 
of conflicts evolve. 
 
I performed a sub-analysis of the examination of survival patterns in order to 
characterise the mechanism of injury during the Iraq and Afghanistan conflicts and 
demonstrate any changes in injury pattern. 
 
The dataset from the UK JTTR described in detail in section 2.3 and covering the 10 
years of conflict 2003-12 was used. This data set involved 2,792 UK casualties 
injured or killed during service in Iraq and Afghanistan. The majority of these 
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casualties (2,227, 80%) were a result of hostile action, with the remaining 565 (20%) 
resulting from incidents not involving enemy forces e.g. road traffic collisions.  
 
The most common mechanism of injury was explosive weapons, causing 1,592 
casualties, representing 56% of total casualties and 65% of those from hostile action. 
Gun-shot wounds (GSW) were the next most significant mechanism of injury, being 
the cause of 684 casualties, 28% of total casualties and 31% of those from hostile 
action. Aside from the increased proportion of GSWs in 2003 during the invasion of 
Iraq, the relative proportion of casualties of GSW to injuries from explosive weapons 
remained approximately consistent as the conflicts in Iraq and Afghanistan evolved at 
approximately 1:3. This relationship between wounding patterns is represented 






Figure 2.7: The relative proportion of injuries caused by gunshot wounds (GSW) or 
blast (explosive munitions) encompassing Improvised Explosive Devices, mortars, 
rockets mines etc. 
 
 
2.6 Anatomic injury patterns 
As outlined in section 1.1 of Chapter One, it is believed that several factors, 
including improvements in body armour, may have resulted in an increased 
proportion of injuries involving the extremities. This phase of this work sought to test 
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whether the anatomic regions injured changed over the course of the conflicts in Iraq 
and Afghanistan. 
 
2.6.1 Have anatomic injury patterns changed? Methods 
In order to determine whether anatomic injury patterns changed over the course of 
the Iraq/Afghanistan conflicts, I requested that Dr Bishop build a similar multinomial 
log-linear regression model using the same 10 year dataset from the UK JTTR as 
previously described in section 2.3.1.  
 
The model was used to examine the distribution of total recorded injuries across the 
eight AIS body regions by year of injury. The categorical outcome variable, body 
region of injury, was coded with ‘Abdomen’ set as the reference level as the 
proportion of injuries affecting this region was stable over the study period. Year of 
injury was modelled using a restricted cubic spline to allow for flexible non-linear 
relationships between time and region of body injury. Model fitting of this complex 
data was performed using a quasi-Newton optimization method due to the potential 
for convergence problems using standard optimization algorithms. Injuries to body 
regions were assumed to be clustered by individual: standard errors were estimated 
using a cluster bootstrap approach based on 10000 samples to account for this. 
 
Observed proportions of injuries by body region and year of injury were analysed for 
temporal trend using the Cochran-Armitage test.  Although there is evidence that the 
proportion of injuries by body region is associated with year (p<1e-11) the Cochrane-
Armitage test is restricted to testing for linear monotonic trends. We wished to 
examine how the relative distribution of injuries across body regions changed over 
time. Models that included non-linear functions of time provided an improved fit to the 
data and were used for the analyses. 
 
2.6.2 Have anatomic injury patterns changed? Results 
During the ten year study period, 14,071 injuries were sustained by the 2,792 
casualties, distributed across body regions as shown in Table 2.6. The extremities 
were the most commonly injured body regions, comprising 43% of all injuries. The 
relative distributions of injuries affecting the abdomen, thorax, spine, face, neck and 

























2003 320 43 (13) 25 (8) 15 (5) 78 (24) 41 (13) 15 (5) 59 (18) 25 (8) 
2004 263 54 (21) 25 (10) 16 (6) 40 (15) 16 (6) 12 (5) 45 (17) 37 (14) 
2005 241 13 (5) 19 (8) 20 (8) 27 (11) 26 (11) 10 (4) 50 (21) 58 (24) 
2006 741 140 (19) 75 (10) 36 (5) 118 (16) 57 (8) 35 (5) 116 (16) 86 (12) 
2007 1,964 284 (14) 224 (11) 65 (3) 228 (12) 179 (9) 91 (5) 490 (25) 321 (16) 
2008 1,503 126 (8) 143 (10) 29 (2) 233 (16) 191 (13) 74 (5) 465 (31) 199 (13) 
2009 3,320 282 (8) 422 (13) 95 (3) 414 (12) 470 (14) 225 (7) 842 (25) 501 (15) 
2010 2,599 196 (8) 299 (12) 85 (3) 279 (11) 368 (14) 161 (6) 758 (29) 404 (16) 
2011 1,787 140 (8) 194 (11) 45 (3) 156 (9) 177 (10) 75 (4) 649 (36) 326 (18) 
2012 1,333 117 (9) 134 (10) 47 (4) 204 (15) 91 (7) 58 (4) 393 (29) 250 (19) 

















Table 2.6: Injured regions as defined by AIS system37 per year. NB more than one 
injury possible per region and casualty. 
 
 
The relative risk ratio (RR) of sustaining an injury to the head, relative to sustaining 
an injury to the abdomen (which remained relatively constant), changed by a factor of 
between 0.87 95%CI (0.78, 0.97) and 0.79 (0.68, 0.92) per year from 2006 to 2010. 
Relative risk ratios for head, face and neck injuries for all unit changes in year are 




Figure 2.8: Distribution of head, face and neck injuries over time as proportion of 
total injuries. Shaded regions denote 95% confidence intervals about the predicted 
values obtained from the multinomial logistic regression model. Dots denote 




The relative risk (RR) of sustaining an injury to the lower extremity, relative to the 
abdomen, remained statistically indistinguishable from zero between 2003 and 2010.  
The RRs changed by 1.44 (95%CI 1.25, 1.68) from 2010 to 2011 and by 1.80 
(95%CI 1.41, 2.30) from 2011 to 2012. RRs for lower extremity injuries for all unit 
changes in year are presented in Figure 2.9.  
 
 
Figure 2.9: Distribution of upper and lower extremity injuries over time as proportion 
of total injuries. Shaded regions denote 95% confidence intervals about the predicted 
values obtained from the multinomial logistic regression model 1. Dots denote 
observed proportions. 
 
The predicted probabilities from the logistic regression model display the negative 
trend in the proportion of head injuries (Figure 2.8), and the positive trend in the 
proportion of lower extremity injuries (Figure 2.9) over the study period. Predicted 
probabilities, and corresponding 95% CIs, for receiving an injury to a specific body 
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 %  
(95% CI) 
2003 16 (12, 21) 8 (6, 10) 7 (4, 10) 19 (14, 24) 9 (6, 13) 4 (3, 6) 16 (12, 20) 12 (9, 16) 
2004 16 (13, 19) 9 (7, 11) 6 (4, 8) 18 (14, 21) 9 (7, 12) 4 (3, 6) 18 (14, 21) 13 (10, 16) 
2005 15 (13, 18) 9 (8, 11) 5 (4, 6) 17 (14, 19) 9 (8, 11) 5 (3, 6) 20 (17, 22) 14 (12, 16) 
2006 15 (12, 17) 10 (9, 11) 4 (4, 6) 15 (14, 17) 9 (8, 11) 5 (4, 6) 22 (20, 24) 14 (13, 16) 
2007 13 (11, 16) 11 (9, 12) 3 (3, 4) 14 (12, 16) 10 (8, 11) 5 (4, 6) 24 (22, 26) 15 (13, 16) 
2008 11 (10, 13) 11 (10, 13) 3 (2, 4) 13 (11, 14) 11 (10, 13) 5 (5, 6) 26 (24, 28) 15 (14, 17) 
2009 9 (7, 10) 12 (11, 13) 3 (2, 3) 11 (10, 13) 14 (12, 15) 6 (5, 7) 28 (27, 30) 15 (14, 16) 
2010 7 (6, 8) 12 (10, 13) 3 (2, 4) 11 (9, 12) 14 (13, 16) 6 (5, 7) 30 (28, 32) 16 (14, 17) 
2011 8 (6, 9) 11 (10, 12) 3 (2, 4) 12 (10, 13) 11 (9, 12) 5 (4, 6) 32 (29, 34) 17 (16, 19) 
2012 9 (7, 12) 10 (8, 12) 3 (2, 5) 13 (10, 17) 6 (4, 8) 4 (2, 5) 32 (28, 37) 19 (17, 23) 
 
Table 2.7: Predicted proportions of injuries for each body region by year.  Predicted 
values and 95% confidence intervals obtained from multinomial log-linear model 





2.7 Extremity injuries in survivors 
The findings of the previous sections establish that survival increased over the 
course of the conflicts in Iraq and Afghanistan, and furthermore that injuries to the 
lower extremity became proportionately more frequent during that time. The next 
phase of this work is to look at extremity injuries in greater detail. 
 
The underlying theme of this work is the surgical treatment of combat casualties. 
Although many fatalities in war are killed immediately, some survive long enough to 
require surgical treatment before succumbing to their injuries38. Therefore I wanted 
this section of work to focus solely on those surviving their injuries, and exclude 
those who received some surgical treatment before dying of their wounds. 
 
The aim of the following study was to characterise the range of extremity injuries 
sustained by surviving UK military casualties over the 12 years of conflict in Iraq and 
Afghanistan. Furthermore, this study aimed to define the treatment burden (as a 
feature of length of hospital stay and number of operative procedures) associated 
with extremity injuries sustained on the modern battlefield.  
 
2.7.1 Characterising extremity injuries in survivors: methods  
All cases recorded in the JTTR in the twelve years between the invasion of Iraq on 
the 19th March 2003 and cessation of combat operations in Afghanistan on the 27th 
October 2014 were examined. Casualties who were killed in action or died from their 
wounds were excluded. No distinction was made between casualties injured as a 
result of hostile or non-hostile action. Survivors with AIS codes for extremity injuries 
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(including pelvic fractures) were included. Survivors with spinal injuries but no 
extremity injury were excluded. All extremity injury codes were included, capturing 
patients with soft tissue injuries but no fracture or amputation in addition to those with 
bony injuries. 
 
Data were gathered from the JTTR on patient demographics, injury pattern, surgical 
management and length of hospital stay (LOS). LOS is expressed as median with 
interquartile range (IQR) throughout.  Amputation was defined as traumatic-complete 
or nearly complete at time of initial coding and did not include amputation following 
failed salvage or reconstructive surgery. Only the loss of an extremity at or more 
proximal to the wrist or ankle was included as amputation; i.e. digit loss was not 
regarded as an amputation for the purpose of this study. Fractures of the carpals, 
metacarpals, phalanges, tarsals and metatarsals respectively were each grouped 
together and counted as a single fracture. Bilateral amputations were counted as 
separate injuries, as were fractures in the same limb as an amputation but at a 
different level, e.g. a femoral fracture in a limb with a trans-tibial amputation. 
 
LOS data included the time spent in deployed medial treatment facilities and in the 
Royal Centre for Defence Medicine (RCDM), but did not include re-admission or time 
spent as an inpatient at rehabilitation facilities. A surgical episode was defined as a 
single episode in an operating theatre undergoing surgery and not as separate 
surgical procedures. Surgical episodes were only counted if they addressed an 
extremity injury and only during the initial hospital admission.  
 
As previously, I calculated Personnel Years at Risk (PYAR) between 2008-14 from 
UKDS data. This was based on computerised records of every day spent in either of 
the two operational theatres by each service person. These figures were summed for 
each calendar year and divided by 365 to give the PYAR i.e. the equivalent number 
of personnel deployed for 12 months. For 2003-7, detailed pay records were not 
available, therefore the information was extrapolated from Ministry of Defence (MoD) 
figures on troop levels contained in memoranda to the UK Parliament and is 
regarded as less precise26,27.  
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Descriptive data are given as medians with inter-quartile range (IQR). Continuous 
data (e.g. NISS) was analysed by Mann-Whitney testing using Graphpad Prism 6 
(San Diego, CA, USA) with a threshold for significance set at 0.05. 
 
2.7.2 Characterising extremity injuries in survivors: results 
During the twelve years of combat in Iraq and Afghanistan, UK personnel were 
deployed for 137,174 PYAR, from which 2,348 were injured and survived. Of these, 
1,813 (77%) had extremity injuries, of which 205 (11%) had at least one amputation 
at the level of, or proximal to the carpus or ankle. In the same period 1,530 fractures 
were recorded: 501 (33%) involved the upper limbs and 1,029 (67%) involved the 
lower limbs and pelvis with the remaining injuries involving just the soft-tissues. 
Three hundred and forty four (344/501, 69%) upper limb fractures were open, 
compared to 597 (597/1,029, 58%) lower limb fractures. The temporal distribution of 















2003 17,820 22 4 * 
2004 10,483 31 9 * 
2005 10,767 49 11 * 
2006 13,000 70 20 10 
2007 13,300 254 57 19 
2008 13,513 181 58 16 
2009 11,909 329 89 41 
2010 11,657 329 93 52 
2011 11,771 252 67 35 
2012 11,488 179 52 24 
2013 7,679 98 20 * 
2014 3,787 19 6 0 
Total 137,174 1,813 486 205 
 
Table 2.8: Incidence of extremity injury, long bone fracture and major amputation per 
calendar year of conflict with Population year at risk (PYAR) shown. Years with 





Figure 2.10: Survivors with extremity injury sustained per Population Year at Risk 
(PYAR), per year. 
 
 
Figure 2.11: Schematic showing anatomic distribution of closed and open fractures. 
NB More than one fracture can occur in a single casualty. 
 
 
Explosive munitions were the most common mechanism of injury, seen in 1,090 




Mechanism of injury n (%) 
Explosive 1090 (60) 
GSW 420 (23) 
Fall 86 (5) 
MVC 78 (4) 
Other 139 (8) 
Total 1813 




Total LOS following extremity injury was 24,486 days, or 67 years and 1 month; a 
total of 2,908 surgical episodes were performed on extremities. 
 
Patients with at least one major amputation had a LOS of 51 days (IQR 30-65) and 
underwent a median of seven extremity surgical procedures (IQR 5-9). One hundred 
and three patients lost a single limb, of which twelve were unilateral upper limb 
amputations.  Eighty-five casualties lost two limbs, the majority of which (82/85, 96%) 
lost both lower limbs. Seventeen lost three limbs representing 0.7% of all survivors 
with further detail show in Table 2.10. There were no UK survivors who lost all four 
limbs at or proximal to the wrist or ankle. Levels of limb loss are detailed in Figure 
2.12. 
 
Unilateral lower limb (n=91) 
 
Trans-tibial 64 
Knee disarticulation 11 
Trans-femoral 16 
Bilateral lower limb (n=97*) 
 
Bilateral trans-tibial 12 
Trans-tibial / knee disarticulation 8 
Trans-tibial / trans-femoral 22 
Bilateral knee disarticulation 12 
Knee disarticulation / trans-femoral 17 
Bilateral trans-femoral 26 
Table 2.10. Patterns of amputation. *This figure includes lower limb 
amputation for triple amputees, all of whom lost both legs and an arm. 
NB: not all amputation patterns are shown in this table due to identifiable low 




Figure 2.12: Schematic showing level of amputation. NB more than one amputation 




For casualties with long bone fractures without amputation, LOS was 13 days (IQR 6-
25) with a median of two surgical procedures on their limbs (IQR 1-4). In closed 
fractures LOS was 11 days (IQR 6-32). In open long bone fractures by contrast, LOS 
was 24 days (IQR 13-46) (p<0.0001, Figure 2.13). For closed fractures, median 





Figure 2.13: Scatter plot showing length of hospital stay for patients with open 
versus closed long bone fractures. The horizontal bars represent the median and 
interquartile ranges. Statistical difference as per Mann-Whitney analysis. 
 
 
2.8 Infection in open tibia fractures 
My findings from the analysis of JTTR data in Figure 2.11 of Section 2.7 shows that 
the tibia is the most commonly fractured bone, and that 65% of these injuries are 
open. These findings are based on registry data and therefore lack clinical detail. 
 
Open tibia fractures remain a considerable challenge to the orthopaedic surgeon. 
They are recognised as having the highest rate of infection following open fracture 
compared to other long-bones39, thought due to the limited soft-tissue envelope. 
Open tibia fractures sustained on the battlefield have been reported to have an 
infection rate of 20-30%39, with infection shown to be associated with poor outcomes 
and late amputation40,41. 
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The aim of this phase of work was to move from registry data to clinical notes in 
order to characterise these injuries in greater detail. Specific objectives were to: 
 i) accurately determine the number of open tibia fractures in UK  casualties,  
 ii) establish the rate of infection, and  
 iii) determine factors associated with infection. 
 
2.8.1 Determining the infection rate in open tibia fractures: methods 
The JTTR was searched for cases of survivors with AIS codes encompassing bony 
injuries of the knee, tibia or ankle sustained between the 10 years of the invasion of 
Iraq in 2003 and 31 December 2012. A wide range of codes was chosen to allow 
cases to be individually reviewed in order to avoid missing cases due to coding 
inaccuracies.   
 
The clinical records, X-rays and microbiological results of patients with open 
diaphyseal tibia fractures were reviewed. The following were excluded: cases not 
involving diaphyseal tibia fractures (AO/Muller type 42); cases other than those 
graded by the operating surgeon as grade III in the Gustilo-Anderson (GA) 
classification42, and patients who were managed with a primary amputation within the 
first three surgical episodes.  
 
Data were gathered on demographics, injury and surgical management. For the 
purposes of this study, an injury was deemed to have been infected if the infective 
episode required surgical treatment. A consultant microbiologist analysed all 
microbiological results and determined the causative microorganism. 
 
The influence of the following factors on infection was examined:  
 
A. New Injury Severity Score (NISS). 
B. Mechanism of injury i.e. explosive versus gun-shot injury. 
C. Bone loss43 (Table 2.11). 
D. Requirement for tissue transfer (both local and free flaps).  
E.  Initial stabilisation with an external fixator. 












Minimal: some bone loss but less that 1 cm 
longitudinally around at least 50% of the circumference 
of the shaft but with some cortical contact 
2 Moderate: bone loss between 1 and 2 cm around at 
least 50% of the circumference of the shaft but with 
some cortical contact 
3 Severe: bone loss greater than 2 cm around at least 
50% of the circumference of the shaft but with some 
cortical contact 
4 Segmental bone loss: no cortical contact 
Table 2.11: Bone loss grading system 41 
 
Descriptive data are reported as medians with inter-quartile range (IQR). Continuous 
data (i.e. NISS) was analysed by Mann-Whitney analysis. The remaining five factors 
were analysed by Fisher’s exact test. In interpreting the levels of statistical 
significance, a Bonferroni correction was applied to avoid the increased risk of a 
Type 2 error inherent in multiple comparisons, hence significance was set at 
p=0.0083. 
 
2.8.2 Determining the infection rate in open tibia fractures: results 
The JTTR search identified 445 cases of casualties with bony injury affecting the 
knee, tibia or ankle. Following case note and X-ray review, 353 cases were excluded 
according to the pre-defined criteria. Ninety two patients with 100 severe open tibial 
fractures were therefore eligible for inclusion (eleven patients with bilateral fractures). 
The median age was 25 years (IQR 21.3 – 29.0, mean = 26.0, SD = 5.1).  
 
Three patients were not followed-up for a minimum of 12 months and therefore were 
excluded from the outcome analysis. In the remaining 97 fractures intra-medullary 
nailing was the most common technique for definitive treatment, used in 42 fractures, 
with other fixation methods detailed in Table 2.12.  
 
Management n Time to definitive 
fixation/median days (IQR) 
IM nails  42  3 (2-4) 
Plates/screws 30 3 (3-5) 
External Fixation 7  2 (1-2) 







Conservative 8  - 
 




Limb salvage failed in eleven patients necessitating amputation: in three cases this 
was due to on-going infection. Initial definitive fixation was subsequently revised in 33 
cases (34%), twelve of which were revised to a circular frame for non-union with 
union eventually achieved. 
 
Twenty two cases (22/97, 23%) were complicated by infection. The most common 
causative micro-organism was Staphylococcus aureus with further detail given in 
Table 2.13.  
 
 
Organism n  
S. Aureus 13 (1 MRSA) 
Acinetobactor 3  
Pseudomonas Sp. 2  
Coag. Neg. Staph 1  
Enterobacter Sp. 2  
Unknown 1  
 




A. Injury severity  
The median overall NISS was 17 (IQR 12-22). In the 22 infected cases the median 
NISS was 20 (IQR 15-29) and 17 (IQR 11-22), in the 75 uninfected fractures 
(p=0.0469, Mann-Whitney) as shown in Figure 2.14. This difference was not 
regarded as statistically significant due to the Bonferroni correction that was applied. 
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Figure 2.14: Scatter plot showing the New Injury Severity Score by infected and un-
infected groups. The horizontal lines denote the median and the inter-quartile range. 
 
 
B. Mechanism of Injury 
The majority of fractures in this series were a result of explosive weapons (69/97, 
71%) with the remainder being injured by gunshot wounds (GSW). The proportion of 
injury types was statistically similar in both the infected cohort (GSW = 5/22) and 
uninfected cohort (GSW = 18/75) (p=0.6014, Fisher’s exact test). 
 
C. Bone Loss 
The degree of bone loss after debridement is shown in Figure 2.15. There were four 
cases of segmental bone loss in the infected cohort and none in the uninfected 
group. Bone loss was significantly associated with subsequent infection (p<0.0001, 


















Figure 2.15: Bar chart showing bone loss and infection. 
 
 
D. Vascularised tissue transfer 
Approximately one third of injuries (31/97, 32%) were covered with vascularised 
tissue transfer i.e. both local and free flaps. Twelve of these were performed in cases 
that subsequently became infected (12/31, 39%, p=0.0177, Fisher’s exact test). This 
association was not significant with the application of the Bonferroni correction. 
 
E. External fixation 
An external fixator was applied in the initial phase of management in 61 fractures 
(61/97, 63%). Eighteen of the 22 cases which subsequently developed infection 
(18/22, 82%) and 43 of the 75 (43/75, 57%) uninfected cases were initially stabilised 
with an external fixator (p=0.0443, Fisher’s exact test). This association was not 
significant with the application of the Bonferroni correction. In 46 cases external 
fixation was converted to internal fixation. The median delay until this occurred was 3 






Reliable data on smoking status was available for 69% of fracture cases. Five of 17 
infected cases (29%) with a recorded smoking status smoked, compared to 18 of 50 
uninfected cases (36%). This difference was not significant (p=0.7704, Fisher’s exact 
test). 
 
2.8.3 Determining the consequences of infection 
A previously published analysis performed earlier on four years of patients from the 
same cohort described in this section found 44 patients with 52 open tibia fractures 
with 12-months of follow-up41. In this series, 19 tibias required revision surgery at 
point of follow-up, with seven requiring amputation, an overall revision rate of 50% 
(26/52).  
 
Infection was defined, as it was in section 2.8.1 as a clinical diagnosis requiring 
surgical treatment. There was a statistically significant association between deep 




The findings of the analysis of the casualty data from the JTTR demonstrates a 
sustained improvement in survival amongst UK military personnel injured whilst 
deployed in Iraq and Afghanistan over the years of conflict. This trend is seen using 
both an anatomic (NISS) or combined anatomic/physiological (TRISS) measure of 
injury severity. Unsurprisingly it appears that the greatest improvement in survival 
occurred in the first half of the conflicts compared to the more modest improvements 
in the second half. 
 
My analysis of injury mechanisms and anatomic distribution reveal that the majority 
of injuries were the result of explosive weapons, and that 77% of survivors had 
injuries to their extremities. 
 
The tibia was the most commonly fractured bone amongst survivors, of which 65% 
were open. An open fracture was associated with a significantly greater number of 
surgeries and length of hospital stay.  
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The infection rate for battlefield open tibia fractures was 23%, with 60% of these 
infections caused by S. aureus. Infection in open tibia fractures was strongly 
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Chapter Three:   Methodology and Model Development 
 
3.0 Introduction  
High-quality clinical studies examining factors that affect infection following 
open fractures are challenging due to substantial variation amongst patients, 
specifically with respect to their injuries and their treatment. This 
heterogeneity risks confounding clinical research. To overcome this, clinical 
studies have to recruit hundreds of patients and can take many years to report 
findings which might help guide clinical practice1,2.  
 
While randomised clinical trials will likely remain the highest standard of 
clinical research, the gap between the level of understanding required in order 
to design safe clinical research studies and the knowledge produced by in 
vitro or ‘lab-top’ work is vast. 
 
Animal models provide translational research between in vitro studies and 
clinical studies: they allow broad principles to be tested, dosages to be refined 
and research questions to be clarified3. Although there is a compromise 
between reality and reproducibility, they allow testing of interventions not 
sanctioned for clinical trials and save research money for the pursuit of only 
the most promising therapies. Furthermore, there is a versatility in animal 
models that allows rapid progress in developing themes as well as the direct 
comparison of multiple treatment modalities. 
 
Studies using animal models of open fracture offer the potential to test 
concepts and evaluate novel treatments or treatment algorithms in a 
reproducible, standardised setting where all variables other than those under 
investigation can be controlled and results obtained rapidly.  
 
 
3.1 Ethical and Legal Framework for Animal Research  
This research work was completed in the US Army Institute for Surgical 
Research (USAISR) in San Antonio, Texas. USAISR is the Department of 
Defence’s principal facility for conducting research aimed at improving combat 
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casualty care. It employs approximately 700 people and includes a large 
animal laboratory licenced to conduct research using a range of species from 
rodents to large animals including primates. 
 
All research involving mammals at the USAISR is governed by US Animal 
Welfare Act of 1966 in accordance with the Guide for the Use and Care of 
Laboratory Animals4. Each individual study was registered with the USAISR 
Institutional Animal Care and Use Committee (IACUC). 
 
 
3.2 Model Selection 
Using an animal to model infection after open fracture accepts limitations due 
to differences in anatomy and physiology and the restrictions in creating a 
contaminated ‘traumatic’ injury in a controlled and reproducible way. All 
medical research using animals represents modelling an injury or pathology 
rather than perfectly recreating it. It is important that these limitations and 
compromises are acknowledged and understood. 
 
With respect to species selection, the closer the species to Homo sapiens, 
then the smaller anatomic and physiological differences will be. However, it is 
a principle of scientific animal work that research should be performed on the 
‘lowest’ animal species that would still permit valid conclusions to be drawn 
from the data generated by the study4. For this reason animal models of bone 
healing and infection have typically used mice, rats and rabbits, although 
sheep and dogs have also been used.5,6 
 
The planned studies that make up the animal proportion of this body of work 
are either testing concepts or screening potential treatments. Therefore, 
although higher primates might present the ideal theoretical choice, that 
degree of very close approximation is unlikely to be scientifically necessary 
and is not ethically or financially justified.  
 
Aside from the ethical imperative already described, the advantages of 
smaller animals e.g. rats, are cost, simpler animal husbandry requirements, 
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and more rapid recovery after surgical procedures. The disadvantages 
associated with smaller animals are the constraints on venepuncture due to 
animal morbidity and pain, which means that intravenous sampling or drug 
administration is extremely limited. There are technical limits due to size on 
the complexity of surgical procedures that it is possible to perform on small 
animals, limiting the nature of some investigations. 
 
Animal models of musculoskeletal infection have predominantly attempted to 
mimic four clinical situations: 
 
 i) Osteomyelitis 
 ii) Infected prosthesis 
 iii) Traumatic wound/open fracture infection  
 iv) The presence of a co-morbidity e.g. diabetes 
 
Creating an animal model to study infection in a traumatic wound/open 
fracture is challenging for the following reasons: 
 
i) Severity of injury. The outcome of interest is usually infection 
after injury. i.e. the presence or absence of infection at a minimum of 
48 hours and usually several days after injury. This requires a balance 
to be established between the severity of the injury created, and the 
need for the animal to be pain-free and relatively mobile until 
euthanasia. For example, it is inhumane to leave an animal with an un-
stabilised fracture, therefore a fracture must either be stabilised 
(internally or externally), or the bony injury must be limited e.g. a drill 
hole through a single cortex. 
 
ii) Open or closed wounds. By definition, traumatic wounds are 
open to the environment. However, in order to standardise the amount 
of bacterial inoculation between animals and to avoid cross-
contamination, wounds in animal models have to be sealed with 
dressings or primarily closed with sutures immediately after inoculation. 
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Clearly this is different from the clinical reality that the model is 
attempting to mimic. 
iii) Non-human immunology and healing. Non-human species
differ from humans in ways that are poorly understood in their response 
to infection and their ability to heal following an injury e.g. the size of a 
bone defect that will not heal spontaneously.  
3.3 Methodology of Contaminated Rat Femur Segmental Defect 
The USAISR has adapted a rat model of a contaminated femur defect first 
described by Chen et al. in 20027. This model has the versatility of being able 
to examine infection and bone healing as an outcome either separately or 
concurrently in the same study. As a small animal model it is well suited to 
translational work examining treatments hitherto based on in vitro work or 
proof of concept studies. 
3.3.1 Surgical Procedure 
Immunologically intact adult male Sprague-Dawley rats (Harlan Laboratories, 
Indianapolis, Indiana) weighing between 350 and 400g on the day of surgery 
were anesthetised with 2% isoflurane. The fur over their right leg was shaved 
and the skin prepared with povodine iodine and 70% isopropanol. An 
incision was made in the skin originating over the greater trochanter and 
continuing distally towards the knee, centred over the femoral shaft. The 
femoral shaft was exposed and stabilized with a bespoke contoured 
polyoxymethylene plate, secured with six threaded Kirschner wires (K-wires) 
inserted under power. This allowed the humane stabilisation of a bony 
defect, and had the effect of introducing an implant to lower the bacterial 
inoculum required for infection8. 
A 6mm defect was created in the mid-shaft of the femur with a reticulating 
saw (Series 1000, Microaire, Charlottesville, US) under continuous saline 
irrigation as shown in Figure 3.1. A 6mm defect has previously been shown to 




Figure 3.1: A microradiograph showing a proximally disarticulated rodent 
femur with 6mm segmental defect. Also visible are six threaded Kirschner 
wires (K-wires) used to fix the radiolucent polyoxymethylene ‘plate’ conferring 
stability despite the defect. 
 
 
The bony defect was contaminated with 30mg of sterile bovine collagen 
soaked with 1 × 105  Colony Forming Units (CFU) of Staphylococcus aureus 
in 0.5mls of saline. The (Xenogen 36) strain of S. aureus used derived from 
ATCC strain 49525, originally from a septic human patient and modified to 
emit photons as shown in figure 3.2 below. (Caliper LifeSciences, CA, USA). 
This strain of bacteria has been regarded by other investigators as being an 
appropriate choice for modelling musculoskeletal infection9. The wound was 
then closed with continuous nylon sutures to the fascial layer and surgical 




Figure 3.2: A limited spectrum photograph of a Kirby–Bauer antibiotic 
sensitivity test of the Xenogen-36 photon-emitting strain of S. aureus used in 
this model. Disc 1 = tobramycin; Disc 2 = gentamicin; Disc 3 = vancomycin.  
 
 
Six hours after the original procedure animals were re-anesthetised. The 
wounds were opened and all the contaminated collagen was meticulously 
removed: any necrotic or soft tissue of dubious viability was excised. The 
wound was then irrigated with 60ml of sterile saline delivered at low pressure 
from a hand-held syringe held at 10cm from the surgical field. At this stage 
any local treatments were applied: wounds were then similarly closed in 
layers. The animals were recovered and allowed full mobility, food and water.  
 
Fourteen days after simulated injury the animals were euthanised after 
isoflurane anaesthetic, with an intra-cardiac injection of potassium chloride. At 
this stage, the hip joint was disarticulated. Under sterile conditions the wounds 
were opened through the healed incision, and the bone defect exposed. The 
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wound was photographed with a photon-count camera (Xenogen IVIS 
Imaging System 100 series, Caliper Life Sciences, Hopkinton, MA). Samples 
of tissue were taken for histological analysis at this stage. 
 
The femur and implant material were stripped of soft tissue and separated. 
The bone tissue was snap frozen in liquid nitrogen and crushed.  Bone and 
implant samples were sent separately for standard quantitative 
microbiological analysis. Crushed bone samples are homogenized with 10ml 
sterile saline in an agitator; implant specimens were rinsed with 10ml of sterile 
saline in an agitator. Aliquots from individual specimens were sequentially 
diluted and spread onto Tryptic-Soy-Agar plates. After overnight incubation at 
37˚C, bacterial colonies were counted and recorded: the threshold of 
detectability was 30 CFU/g. Confirmation that the bacterial colonies being 
counted were from the original, contaminating S. aureus was obtained by 
further imaging using the photon count camera. 
 
 
3.3.2 Outcome Measures 
Depending on the study, different outcome measures can be examined: 
 
i. The presence of detectible bacteria in bone; 
ii. The quantity of bacteria in bone tissue in CFU/g; 
iii. The presence of detectible bacteria on the implant material 
(polyoxymethylene plate and K-wires); 
iv. The quantity of bacteria on the implant material in CFU/g; 
v. The photon-count of the wound; 
vi. Radiological evidence of defect healing (micro CT or radiograph); 
vii. Histological evidence of defect healing; 
 
There is clearly a spectrum between contamination (presence of bacteria), 
colonisation (persistence and multiplication of bacteria), and infection 
(pathological effect of bacteria multiplying bacteria and resulting 
inflammation). Just as there is no clear definition of infection in the clinical 
setting, neither is there one in animal research10,11.  
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The widely used US Centre for Disease Control criteria for defining infection 
still relies in part on subjective clinical diagnosis of infection i.e. a case is 
infected when the treating physician judges it to be so. For the purposes of 
these studies using this rodent model it was decided to adopt an 
unambiguous definition of infection as the primary outcome measure: the 
persistence of detectable bacteria in the bone or on the implanted hardware 
after 14 days from ‘injury’. This definition was used to avoid the obvious 
problems with a subjective ‘diagnosis’ of infection in an animal model.  The 
secondary outcome measure was the quantity of recovered bacteria 
measured separately from the bone and implant samples. 
 
 
3.3.3 Statistical Analysis 
The categorical data for the presence of bacteria in the bone and on the 
hardware from study groups were compared using Fisher’s exact test. The 
quantity of bacteria in the bone and on the hardware for each animal was 
summed and log transformed before being averaged across each group. 
Pairs of groups were directly compared using a Mann-Whitney test while 
ANOVA of results across a range of groups was calculated using a student 
Newman-Kuells test. 
 
3.4 Model Development 
The model described in Section 3.3 has previously been used in USAISR to 
examine infection in open fractures12. However, in previous studies a bacterial 
inoculation of 1×105 CFUs of S. aureus with surgical treatment 6 hours later 
produced universal infection in all animals. Investigators therefore used the 
differences between the quantity of bacteria recovered from animals in 
different treatment arms to determine the possible effects of each treatment. 
Furthermore, the primary outcome measure used in the rodent model at 
USAISR had been the photon count, i.e. measuring photons produced by the 




I identified that the previous use of this model had the following problems: 
 
1. The rodent model did not mimic the clinical scenario it was attempting 
to model as closely as it could. 
The modelled 100% presence of infection is markedly different from the 
clinical setting where infection rates of less than 50% are typically seen 
after open fracture13,14. With previous use of the model, investigators 
had to judge the potential efficacy of treatments based on 
differentiating between ‘infected’ and ‘very infected’ wounds.  
 
2. The reliance on photon counts of the wound bed was vulnerable to 
confounders: the wound had to be opened and a 3-dimensonal 
structure rendered into a 2-dimensional image to be measured by the 
photon camera.  
 
To maximise the potential for the results of the animal studies to translate to 
clinical trials, the model needed to mimic the clinical reality of infection more 
closely, by: 
 
1. Establishing a more clinically appropriate balance between infected 
and uninfected wounds; 
 
2. Incorporating systemic antibiotic treatment within the model. 
 
To achieve this, the following objectives were established:  
 
1. Determine the bacterial inoculation resulting in infection rate of 50%; 
 
2. Establish a systemic antibiotic treatment regime that results in a 






3.5 Bacterial Inoculation  
In order to determine the relationship between initial bacterial inoculation and 
subsequent infection a model development study was performed. 
 
3.5.1 Bacterial Inoculation: Methods 
The standard model described above in Section 3.3 was used. Fifty rats were 
divided into five groups of ten rats each. Each group was inoculated with a 
different quantity of bacteria, increasing in orders of magnitude from 1 × 101 to 
1 × 105 CFUs.  
 
Animals were treated with surgical debridement including irrigation with 60mls 
of sterile saline at 6 hours from time of injury; no antibiotics were given. 
Animals were euthanised 14 days after initial inoculation: the plate and K-
wires were retrieved and separated from the femur. Both samples were 
processed separately as described above.  
 
3.5.2 Bacterial Inoculation: Results 
No bacteria were detectable in animals inoculated with 1 × 101 CFU, whilst all 
animals inoculated with 1 × 103 CFUs and greater had bacteria detectable on 





Figure 3.3: Proportion of samples with detectible bacteria in each group of 10 
animals (maximum of 20 samples per group) 14 days after inoculation with 
various quantities of bacteria, given in colony-forming units (CFUs). P-values 
calculated with Fisher’s exact test shown. 
 
 
In the group inoculated with 1 × 102 CFUs approximately half of the animals 
had detectable bacteria. This group had a mean bacterial level of several 
hundred CFU/g. All groups inoculated with more bacteria had similar levels of 
bacteria, of an order of magnitude greater than the group inoculated with 1 x 
102 CFUs, as shown in Figure 3.4 and Table 3.1.  
 
When the model was inoculated with 1 × 102 CFU, bacteria were recoverable 
from approximately 50% of animals at 14 days, equating to a 50% infection 
rate. 
 
















































Figure 3.4: Quantification of bacteria recovered from animals (10 per group) 
14 days after inoculation with various quantities of bacteria, given in colony-
forming units (CFUs). Error bars show standard error of the mean, p-values 
by Mann-Whitney test given. 
 
 
 Quantity, CFU 
 1 × 10
1 1 × 102 1 × 103 1 × 104 1 × 105 
Bone mean 0 7.21 × 104 7.83 × 105 1.11 × 105 1.51 × 105 
Bone SEM 0 4.40 × 104 1.35 × 105 1.92 × 104 1.95 × 104 
Implant mean 0 9.82 × 104 1.65 × 105 2.58 × 104 5.11 × 104 
Implant SEM 0 5.10 × 104 1.61 × 105 3.16 × 103 9.11 × 103 
 
Table 3.1: Quantification of bacteria recovered from animals 14 days after 
inoculation with various quantities of bacteria, given in colony forming units 









































3.6 Systemic Antibiotics  
In order to incorporate a systemic antibiotic regime into the model and better 
understand the relationship between systemic antibiotics and infection, the 
following study was performed. 
 
3.6.1 Systemic Antibiotic Regime: Methods 
The standard model described above in Section 3.3 was used. Eighteen rats 
were divided into three groups of six rats each. Each animal was inoculated 
with 1 × 105 CFUs of S. aureus, and had their wounds surgically treated with 
debridement and irrigation with 60mls of sterile saline. At the time of 
debridement each animal was treated with subcutaneous cephazolin. The 
initial dose range of antibiotic to be given was based on an assumed weight of 
400g per rat. The dose of antibiotic given varied between each group: 2mgKg-
1, 5mgKg-1 and 10mgKg-1. Further administrations of the same dose were 
repeated at 12 hourly intervals for 72 hours, so that each rat received a total 
of 7 doses.  
 
Animals were euthanised 14 days after initial inoculation: the plate and K-
wires were retrieved and separated from the femur. Both samples were 
processed separately as described above.  
 
3.6.2 Systemic Antibiotic Regime: Results 
All samples in animals treated with 2 mgKg-1 had detectible levels of bacteria: 
no animals treated with 10 mgkg-1 of cephazolin had any bacteria detectible 
on their bone or hardware. In the group treated with 5 mgKg-1 of cephazolin, 
approximately half of the animals had samples positive for bacteria, as shown 




Figure 3.5: Proportion of samples with detectible bacteria in each group of six 
animals (6 animals per group therefore a maximum of 12 samples per group) 
14 days after inoculation with 1 × 105 CFU of S. aureus and treatment with 
various doses of systemic cephazolin for 72 hours. P-values by Fisher’s exact 
test shown. 
 
The relationship between antibiotic treatment dose and and subsequent 
bacterial quantification is shown in Figure 3.6 and in Table 3.2 below. 
 















































Figure 3.6: Quantification of bacteria recovered from animals (n=6 in each 
group) 14 days after inoculation with 1 × 105 CFU of S. aureus and treatment 
with various doses of systemic cephazolin for 72 hours. Error bars show 










Bone mean 0 7.21 × 104 7.83 × 105 
Bone SEM 0 4.40 × 104 1.35 × 105 
Implant mean 0 9.82 × 104 1.65 × 105 
Implant SEM 0 5.10 × 104 1.61 × 105 
 
Table 3.2: Quantification of bacteria recovered from animals 14 days after 
inoculation with 1 × 105 colony-forming units (CFUs) of S. aureus and 
treatment with various doses of systemic cephazolin for 72 hours. Results are 












































The contaminated rodent femur segmental defect model used at USAISR 
uses an established and well described methodology for examining bony 
infection in the context of an injury. The model has advantages of its ethical 
acceptability, versatility, short study time and relatively low cost. 
 
The model development studies achieved the aim of incorporating a clinically 
appropriate systemic antibiotic treatment regime into the model. Furthermore 
the infection ’tipping point’ at which approximately 50% of animals were 
infected was achieved both with and without systemic antibiotics. 
 
3.8 References 
1. Anglen JO. Comparison of soap and antibiotic solutions for irrigation of 
lower-limb open fracture wounds. A prospective, randomized study. J Bone 
Joint Surg Am 2005;87-7:1415-22. 
2. FLOW Investigators, Bhandari M, Jeray KJ, Petrisor BA, Devereaux 
PJ, Heels-Ansdell D, Schemitsch EH, Anglen J, Della Rocca GJ, Jones C, 
Kreder H, Liew S, McKay P, Papp S, Sancheti P, Sprague S, Stone TB, 
Sun X, Tanner SL, Tornetta P, 3rd, Tufescu T, Walter S, Guyatt GH. A 
Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. 
N Engl J Med 2015;373-27:2629-41. 
3. Horig H, Pullman W. From bench to clinic and back: Perspective on the 
1st IQPC Translational Research conference. J Transl Med 2004;2-1:44. 
4. National Research Council (U.S.). Committee for the Update of the 
Guide for the Care and Use of Laboratory Animals., Institute for 
Laboratory Animal Research (U.S.), National Academies Press (U.S.). 
Guide for the care and use of laboratory animals. 8th ed. Washington, D.C.: 
National Academies Press, 2011:xxv, 220 p. 
5. Mills LA, Simpson AH. In vivo models of bone repair. J Bone Joint Surg Br 
2012;94-7:865-74. 
6. Cremieux AC, Carbon C. Experimental models of bone and prosthetic 
joint infections. Clin Infect Dis 1997;25-6:1295-302. 
7. Chen X, Kidder LS, Lew WD. Osteogenic protein-1 induced bone 
formation in an infected segmental defect in the rat femur. J Orthop Res 
2002;20-1:142-50. 
8. Petty W, Spanier S, Shuster JJ, Silverthorne C. The influence of skeletal 
implants on incidence of infection. Experiments in a canine model. J Bone 
Joint Surg Am 1985;67-8:1236-44. 
9. Pribaz JR, Bernthal NM, Billi F, Cho JS, Ramos RI, Guo Y, Cheung AL, 
Francis KP, Miller LS. Mouse model of chronic post-arthroplasty infection: 
noninvasive in vivo bioluminescence imaging to monitor bacterial burden for 
long-term study. J Orthop Res 2012;30-3:335-40. 
10. Metsemakers WJ, Kuehl R, Moriarty TF, Richards RG, Verhofstad 
MH, Borens O, Kates S, Morgenstern M. Infection after fracture fixation: 
Current surgical and microbiological concepts. Injury 2016. 
	 67 
11. Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, 
McFadyen I, Scarborough M, Athanasou NA, Ochsner PE, Kuehl R, 
Raschke M, Borens O, Xie Z, Velkes S, Hungerer S, Kates SL, Zalavras C, 
Giannoudis PV, Richards RG, Verhofstad MHJ. Fracture-related infection: 
A consensus on definition from an international expert group. Injury 2017. 
12. Brown KV, Walker JA, Cortez DS, Murray CK, Wenke JC. Earlier 
debridement and antibiotic administration decrease infection. J Surg Orthop 
Adv 2010;19-1:18-22. 
13. Penn-Barwell JG, Bennett PM, Mortiboy DE, Fries CA, Groom AF, 
Sargeant ID. Factors influencing infection in 10 years of battlefield open tibia 
fractures. Strategies Trauma Limb Reconstr 2016;11-1:13-8. 
14. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. 
Infectious complications of open type III tibial fractures among combat 

























































































Chapter 4:    Timing of Treatment 
 
4.0 Introduction 
As described in Chapter one, the debate about the urgency of debriding open 
fractures, and the relationship with subsequently developing infection, is on-going. 
Recently, practice has shifted away from the previous doctrine of debriding open 
fractures as an emergency, commonly referred to as the ‘six hour rule’1.   
 
This shift is exemplified by the change in the clinical standards published by the 
British Orthopaedic Association (BOA) and British Association of Plastic, 
Reconstructive and Aesthetic Surgeons (BAPRAS) on the management of open tibial 
fractures. In 1997 they stated that, “The first orthopaedic procedure should be 
undertaken within six hours of injury”2. In the 2009 revision of these guidelines the 
‘six hour rule’ had been explicitly laid aside in favour of debridement, “Within 24 
hours of injury”3.  
 
This evolution was based on clinical evidence demonstrating that provided the 
patient received early antibiotics, the debridement could be safely delayed until it 
could be performed by a combined senior orthopaedic and plastic surgical team. This 
approach was felt to be preferable to an ‘out-of-hours’ emergency procedure by a 
junior orthopaedic trainee, with the potential for inadequate debridement and 
compromise of definitive reconstructive surgery.  
 
The evidence from clinical and animal studies examining the relationship between 
timing of debridement and administration of antibiotics is inconsistent. The majority of 
clinical evidence comes from retrospective observational cohort studies, which 
suggest that surgery can safely be delayed by 12-24 hours following antibiotic 
administration without increasing the risk of infection4-6. Conversely, the animal 
studies that examine this relationship have concluded that delay to surgical treatment 
is closely related to the development of infection7. 
 
The contradictory conclusions reached by these two study types are likely due to 
their respective design weaknesses. Animal studies have looked at either the timing 
of systemic antibiotics8 or surgery9, and therefore do not examine the possibility that 
antibiotic drugs can render surgical delay ‘safe’. Conversely, observational studies 
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are susceptible to selection bias with a tendency for clinicians to delay the 
debridement of cleaner, simpler fractures over contaminated, complex ones with the 
risk of masking the independent effect of surgical delay1. Unfortunately, the multiple 
confounders that exist in the clinical setting can never be ethically controlled for in a 
prospective study. 
 
This aim of this study is to examine the relationship between the delay from injury to 
surgical debridement and antibiotic treatment, and subsequently developing infection.  
 
4.1 Timing of Treatment: Methods 
This study used the rodent model of a contaminated segmental femur defect 
described in Chapter 3. Inoculation with 1x105 Colony Forming Units (CFUs) of 
Staphylococcus aureus (S. aureus) was used to contaminate the segmental defect.  
 
At a specified time after the initial ‘injury’ (2, 6, or 24 hours), the animals were re-
anesthetised, their wounds opened, debrided and irrigated with 60 ml of sterile saline 
at low pressure. 
  
Fourteen days after simulated injury the animals were euthanised. The femur and 
implants were stripped of soft tissue and separated. Bone and implant samples were 
sent separately for standard quantitative microbiological analysis. 
 
4.1.1 Antibiotic Treatment 
In addition to surgical debridement, the rats received antibiotic therapy (5 mg/Kg of 
cephazolin (Sigma-Aldrich, St Louis, MO, USA) sub-cutaneously). The animals 
received the initial dose of antibiotic at a specified time period after initial injury (2, 6, 
or 24 hours), and every twelve hours thereafter for a total of seven identical doses. 
This regimen was selected for the following reasons:  
 
1) Approximation of clinical practice, where a 72 hour course of antibiotic therapy 
is recommend3; 
2) Model development studies described in Chapter 3 demonstrated a 50% 
infection rate when this dose of antibiotics and debridement occured six hours 
after injury.  
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4.1.2 Study Groups 
Seventy rats were divided into seven groups of ten rats each. All groups were treated 
with identical surgery and antibiotic regimens initiated at different time points of 2, 6 
and 24-hours. These time points were chosen to approximate clinical practice: 
o 2 hours: the time typical for surgical debridement in the military setting; 
o 6 hours: the previous clinical goal, and the time at which preclinical studies 
indicate biofilm formation and maturation in bone10. 
o 24 hours: the proposed maximum operative delay that can safely be 
contemplated with the objective of ensuring sufficient surgical expertise.   
 
The timings of surgical debridement and antibiotic administration for each study 
group are shown in Table 4.1. In an effort to minimise animal use it was decided not 
to study 24 hour antibiotic administration with 6 hour or 24 hour surgery for the 
following reasons: 
1) Previous model development studies described in Chapter 3 indicated these 
groups would be statistically indistinct; 





 2hr Antibiotics 6hr Antibiotics 24hr Antibiotics 



























Figure 4.1: Mean bacterial quantification results of varying treatment timings with 
statistical groupings by combined bone and hardware results.  Error bars showing 
standard error of the mean. Different letters signify a difference among groups, 
p<0.05, and the same letter indicates no difference. 
 
 
No animal that received both antibiotics and surgery at two hours after injury had 
detectible bacteria, whilst every animal in the group which had either treatment 
delayed for 24 hours had detectible bacteria in either hardware or bone or both as 





Figure 4.2: Proportion of samples from each treatment group with detectible 
bacteria. Y-axis shows the number of samples with positive bacterial, for each group 
of 10 animals, there were 10 hardware samples and 10 bone samples, a total of 20. 
 
 
In the three groups of animals that received antibiotics at two hours, delaying surgery 
from two to six hours resulted in a significantly greater number of positive samples 
from 0 to 5 (p=0.047), however further delay to surgery from six to 24 hours, did not 
cause a significant increase in bacterial quantity or number of positive samples (5 vs 
12, p=0.054) as detailed in Table 4.2. This was confirmed by ANOVA of bacterial 
quantification across these three groups. 
 
If antibiotic administration did not occur within 6 hours of injury, delaying surgery from 
6 hours to 24 resulted in a higher significant increase in proportion of samples that 
were positive for bacteria (p=0.002). 
 
In order to determine whether antibiotics or surgery had a more temporally significant 
effect on bacteria, two pairs of ‘mirrored’ study groups were compared. The first was 
a pair of groups in which the timing of surgery and antibiotics was reversed around 
the two and six hour time points, the second in which treatments occurred at two and 
24 hours. In both comparisons, earlier antibiotics had a significantly greater impact 
on the proportion of positive samples than earlier surgery. At the two and six hour 
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treatments, the p value was 0.004 and for the 6 and 24 timings it was 0.003 as 




























Group 1 - 0.047 0.001 0.001 0.003 < 0.001 < 0.001 
6hr 
Group 2 0.047 - 0.054 0.004 0.501 < 0.001 < 0.001 
24hr 




Group 4 < 0.001 0.004 0.501 - 0.054 0.408 0.00471 
6hr 
Group 5 0.003 0.501 0.344 0.054 - 0.002 < 0.001 
24hr 




Group 7 < 0.001 0.001 0.004 0.0471 < 0.001 0.487 - 
Table 4.2: Metric table showing p-values of direct comparisons between treatment 
groups according to Mann-Whitney analysis of the presence of the quantification of 
bacteria from recovered samples. Each study group can be identified in the columns 





  2 hr Antibiotics 6 hr Antibiotics 24 hr Antibiotics 













2 hr - * * * * * * 
6 hr * - NS NS NS * * 
24 hr * NS - NS NS NS * 
6 hr 
Antibiotics 
2 hr * NS NS - NS NS NS 
6 hr * NS NS NS - * * 
24 hr * * NS NS * - NS 
24 hr 
Antibiotics 2 hr * * * NS * NS - 
Table 4.3: Statistical differences between treatment groups according to Fisher’s 












The findings of this study demonstrate the importance of patients receiving antibiotic 
therapy and surgical debridement early. 
 
These findings are consistent with previous work, which has described the progress 
of bacteria from its colonizing planktonic form to adherence to tissue and eventually 
the formation of biofilm, the so-called ‘race to the surface’11. As bacteria progress 
through these stages, their vulnerability to conventional treatments of debridement, 
irrigation and antibiotics decreases; the six-hour time point appears to be 
significant10.    
 
Even when open fractures receive very early antibiotics, the findings of this study 
support the position that early surgical treatment can still reduce infection. However, 
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Chapter Five: Novel Treatments of Open Fractures  
 
5.0  Introduction 
In Chapter Three the association between infection and poor outcome following 
open fracture was defined. Furthermore, it was established that the tibia is the most 
common open fracture seen in surviving battlefield casualties, and the infection rate 
following this injury is 23%. 
 
Identifying novel treatments with the potential to reduce the infection rate following 
open fracture should improve outcomes for those injured in combat in the future. 
 
5.1  Irrigation with Chlorhexidine Solution Versus Saline 
As described in Chapter one open fracture wounds are irrigated or rinsed with a fluid 
to physically remove contamination and microbes. Since Lister first described 
irrigating open fracture wounds with carbolic acid solution in 18671, surgeons have 
experimented with a variety of antiseptic chemicals to irrigate wounds.  
 
An antiseptic chemical is one that is toxic to microbes with the potential to cause 
infection. The rationale for their use in infected wounds is that those microbes not 
physically removed by the mechanical effect of inert fluids will be killed by the 
antimicrobial action of the antiseptic. 
 
Irrigation of open fracture wounds with antiseptic solutions was performed on a 
massive scale fifty years after Lister’s work during the First World War. As a 
Lieutenant in the Royal Army Medical Corps, Alexander Fleming studied the effect of 
irrigating battlefield wounds with antiseptic solutions.  
 
Fleming took large numbers of microbiological samples from wounds before and after 
surgical treatment, and noted the solution used to irrigate those wounds. His findings 
from this purely observational work led him to believe that wounds irrigated with 
antiseptics had greater rates of infection than those irrigated with saline. He 
concluded that: ‘All the great successes of primary wound treatment have been due 
to efficient surgery, and it seems a pity that the surgeon should wish to share his 
glory with a chemical antiseptic of more than doubtful utility.’2 
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Despite Fleming’s scepticism about the efficacy of antiseptic solutions which he 
shared in a 1919 lecture to the Royal College of Surgeons2, the use of antiseptics in 
this way continued for the century from the end of the First World War until the 
present. 
 
The use of antiseptic solutions in surgery has recently been the focus of much 
scientific interest and research. The authors of the Fluid Lavage of Open Wounds 
(FLOW) study aimed to determine North American orthopaedic trauma specialists’ 
attitudes towards the use of irrigation fluids in contaminated wounds. They found that 
around half of the 984 respondents thought that irrigation with chlorhexidine solution 
would be more effective than irrigation with saline alone3. This survey was limited by 
a response rate of only 56%, and it is worth noting that although half the respondents 
said that that they regarded chlorhexidine as superior to saline, only 2% actually 
used it in their clinical practice. 
 
The disparity between the perceived efficacy and actual utilisation of chlorhexidine is 
likely due to it being widely used by surgeons in an alcoholic solution to 
decontaminate or ‘prep’ skin prior to surgery4. However, there are no published 
animal or clinical trials that have evaluated its use in the irrigation of open fractures5. 
 
The purpose of this study was to compare the efficacy of irrigation with a variety of 
aqueous chlorhexidine solutions to saline in reducing infection in an animal model of 
a contaminated open fracture.  
 
5.1.1 Irrigation Fluids: Study Groups and Methods 
The animal model described in detail in Chapter Three was used with five groups of 
ten animals each. The standard injury was created in each animal before being 
contaminated with 1 × 102 Colony Forming Units (CFUs) of the Xen 36 strain of 
Staphylococcus aureus (S. aureus). 
 
Six hours after injury and temporary wound closure, the wounds were re-opened, 
gross contamination was excised and wounds were irrigated with a total of 60mls of 





Group Animals (n) Treatment 
Control 10 Irrigation with 60 ml 0.9% saline. 
0.5% CHG 10 Irrigation with 60 ml 0.5% CHG aqueous solution.	
0.05% CHG 10 Irrigation with 60 ml 0.05% CHG aqueous solution.	
0.005% CHG 10 Irrigation with 60 ml 0.005% CHG aqueous solution.	
0.05% CHG & 
Saline rinse 10 
Irrigation with 50 ml 0.05% CHG 
aqueous solution followed by rinsing 
with 10 ml 0.9% saline.	
 
Table 5.1: Study groups detailing irrigation fluids used following surgical debridement 
six hours after initial injury and contamination with 1x102 CFU of S. aureus. CHG: 
chlorhexidine 
 
After irrigation, wounds were re-closed and the animals were recovered and survived 
for 14 days. At this point they were euthanized and bone and implants were 
recovered and analysed for the presence of bacteria.  
 
5.1.2 Irrigation Fluids: Results 
There was no statistical difference in the levels of bacteria detected on bone and 
hardware following irrigation with aqueous chlorhexidine at a range of concentrations 
as shown in Figure 5.1 (p-values shown in Table 5.2, Fisher’s Exact Test). 
 
Similarly, there was no difference in the levels of bacteria recovered from animals 
following irrigation with aqueous chlorhexidine compared to saline alone as shown in 
Figure 5.2. P-values for the proportion of samples with detectable bacteria in each 
test group compared to the control group are shown in Table 5.2.  
 
The results of the Kruskal-Wallis Test of the log sums of the bacteria recovered from 
the animal’s wounds across all groups was not significant (p=0.21) and therefore 





Figure 5.1: Proportion of bone and hardware samples with detectible bacteria from 
each group of ten animals 14 days after inoculation with 1x102 CFUs of S. aureus 
and irrigation with various fluids or combinations. No significant differences between 








Test Group p-value of 
comparison 
with control 
0.5% CHG 0.74 
0.05% CHG > 0.99 
0.005% CHG 0.74 
0.05% CHG & Saline rinse 0.20 
 
Table 5.2: The similarity of the effect of various concentrations of CHG on the rate of 
detectable bacteria compared with control group (0.9% saline alone). P-values 



























































Figure 5.2: Mean bacterial quantification of bone and hardware samples 14 days 
after inoculation with 1x102 CFUs of S. aureus and irrigation with various fluids or 
combinations. Ten animals in each study group. Error bars show the Standard Error 




5.2  Local Antibiotic Gel Versus Antibiotic Polymethylmethacrylate ‘Beads’ 
As described in Chapter One in clinical practice antibiotic therapy is initiated as soon 
as possible after a casualty sustains an open fracture. Despite this, infections occur 
in 23% of open tibia fractures as described in Chapter Three.  
 
Antibiotics are typically administered systemically, i.e. orally or intravenously. The 
main disadvantage of systemic antibiotics is that they require repeated dosages to 
achieve and maintain an effective concentration at the site of the wound. Additionally, 
an effective concentration of antibiotic in the wound is only achieved by establishing 
a similar concentration throughout the whole body. This limits the antibiotic 
concentration achievable at the wound to a level which is not toxic to other body 
tissues. 
 
The alternative to systemic delivery is local delivery, where antimicrobials are 
administered directly into the wound, a technique being used in clinical practice even 
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before the widespread use of penicillin. Jensen et al. published their experience of 
local sulphanilamide powder in open fracture wounds in 19396. In this retrospective 
study they attributed the reduction of infection rates from 6/22 (28%) in an historical 
group to 2/41 (5%) to the local administration of sulphanilamide. Although they did 
not present a statistical analysis of their findings, the difference appears to be 
significant (p=0.0177, Fisher’s exact test).  
 
Writing in 1945, Fleming cited the local use of penicillin as an important adjunct to 
systemic treatment 7. However, after the Second World War the use of local 
antibiotics waned as new families of antibiotics were developed and experience with 
systemic administration improved.  
 
It was not until the late 20th century that the advantages of local antibiotic delivery in 
achieving high concentrations of antibiotics within wounds without the need for 
repeated systemic dosing or the potential for causing systemic toxicity was re-
popularised. Klem et al used polymethylmethacrylate (PMMA) cement blended with 
antibiotic powder as a vehicle for local delivery in the eradication of musculoskeletal 
infection8,9. The authors described the use of blocks or lumps of PMMA blended with 
antibiotic as a ‘spacer’ i.e. material used by surgeons to fill a void left after excision of 
normally necrotic or infected material to prevent the void being filled with a 
haematoma with potential to become infected.  
 
Klem’s experience was based on the treatment of established infection, where 
infected, necrotic bone seen in osteomyelitis is excised, and the resulting void filled 
with antibiotic PMMA ‘spacers’. 
 
Writing in 1990, Henry described how he had adapted this technique and used 
PMMA blended with antibiotics to mould beads around a thick suture material to 
facilitate their removal from a wound. He speculated that the larger surface area of 
the beads compared to a spacer allowed greater elution of active antibiotics from the 
PMMA, thereby delivering higher concentrations of antibiotics to the wound and 
reducing infection rates10. Henry advocated the routine use of local antibiotics in the 
form of antibiotic PMMA beads to prevent infection in open fractures. 
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Other methods for local antibiotic delivery include mixing them with either 
autologous11 or synthetic bone graft, e.g. Tobramycin and calcium sulphate, 
commercially available as Osteoset T©12. These techniques are aimed at achieving 
two objectives: treating a bone defect and delivering antibiotics. This is a distinct 
clinical situation than purely the delivery of local antibiotics into a wound. Less than 
10% of tibia fractures13 involve bone loss that might require bone grafting, therefore 
this thesis focused on local antibiotic delivery vehicles that could be used in 
situations with or without bone loss possibly requiring grafting. 
 
PMMA beads probably remain the most commonly used local antibiotic delivery 
vehicle in orthopaedic practice14-16, though there are disadvantages associated with 
their use. The beads are bulky which complicates wound closure, and are not bio-
absorbable thus necessitating surgical removal. Although some authors have 
advocated leaving them in situ17, once they have eluted their antibiotics they act as 
an avascular foreign body and a site for potential bacterial colonization18.  A 
conceptual disadvantage with antibiotic PMMA beads is that they are in essence an 
antibiotic depot requiring diffusion of the antibiotic from high concentrations close to 
the beads to the rest of the wound. This will potentially result in sub-therapeutic 
levels of antibiotics in areas of the wound furthest from the beads. 
 
An idealised local antibiotic vehicle would therefore be: 
§ Bio-absorbable to avoid the requirement for removal; 
§ Degrade at the same rate as antibiotics are eluted to avoid persisting as a 
foreign body without the presence of antibiotics; 
§ Conform to the wound to permit easier wound closure; 
§ Allow similar levels of concentration to be achieved throughout the wound. 
 
The pharmaceutical company Dr. Reddy’s Laboratories, Inc., (Bridgewater NJ), 
(DRL), approached the United States Army Institute of Surgical Research (USAISR) 
after developing a bio-absorbable antibiotic gel that they had been developing for 
preventing surgical site infection in abdominal surgery. DRL claimed that their 
product performed closely to the idealised properties described above. Therefore, 
while working at USAISR, I established a Cooperative Research and Development 
Agreement (CRADA) to allow technology transfer and sharing of intellectual property 
between DRL and USAISR and to permit evaluation of the gel. 
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5.2.1 Local Antibiotic Treatments  
The gel that DRL had developed is a sterile bioabsorbable phospholipid gel, 
designated DFA-02, containing 1.7% vancomycin and 1.9% gentamicin by weight. 
According to information provided by DRL the phospholipid gel was prepared by the 
addition of water to gentamicin sulphate and vancomycin hydrochloride, to allow 
complete dissolution of gentamicin sulfate and vancomycin hydrochloride.  Then, 
lecithin (Phospholipon 90G, Phospholipid, GmbH, Cologne, Germany) and sesame 
oil was added, followed by high shear mixing at 5000 rpm for 60 min to obtain a 
uniform primary emulsion. The primary emulsion was placed in a microfluidizer 
(Microfluidics, Inc. Newton, MA) to produce a monophasic solution. The monophasic 
solution was lyophilized to remove water and obtain a dry paste. The dry paste was 
then mixed with dehydrated alcohol (6% w/w) and heated to form a viscous clear gel. 
The clear gel was filter sterilized by passing the entire mass through a 0.22 micron 
sterilizing filter (Sartorius Stedim, Inc. Bohemia, NY).   
 
Antibiotic PMMA beads were manufactured under sterile conditions using Palacos R 
(Zimmer, Dover OH) arthroplasty cement. 40 g of MMA co-polymer powder was 
blended with 2.0 g of vancomycin (Sigma-Aldrich, St Louis, Missouri) and 2.4 g 
tobramycin sulphate (Sigma-Aldrich) then mixed with 20 ml of MMA monomer liquid. 
A 3mm mould was then used to create beads weighing approximately 20mg and 
containing 3.1% vancomycin and 3.7% tobramycin sulfate by weight. In each animal, 
four beads were placed in the wound, two in the bone defect, and two in the 
surrounding soft tissues; this was the number of beads that reasonably ‘fit’ into the 
wound. This delivered a dose of 2.5 mg of vancomycin and 2.9 mg of tobramycin. 
 
5.2.2 Local Antibiotics: Study Groups and Methods  
The model described in Chapter Three and above in Section 5.1.1 was used. Four 
group of ten animals each were studied, as shown in Table 5.3. 
 
Group Animals (n) Treatment 





Four 3 mm PMMA beads containing 2.5 
mg vancomycin and 2.9 mg tobramycin 
were placed into the wound after irrigation 
and before closure. 
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Two 3 mm antibiotic beads containing 1.25 
mg vancomycin and 1.5 mg tobramycin 
and 0.5 ml of antibiotic gel containing 8.5 
mg vancomycin and 8.5 mg gentamicin 
was placed into the wound after irrigation 
and before closure. 
ABx Gel 
 10 
1ml of phospholipid gel containing 19 mg 
vancomycin and 17 mg gentamicin was 
placed into the wound after irrigation and 
before closure.	
Table 5.3: Study groups detailing different treatments and quantity of antibiotic 
received by each group. ABx: antibiotics, PMMA: polymethylmethacrylate.  
 
All animals were contaminated with 1x105 Colony Forming Units (CFUs) of 
Staphylococcus aureus and treated six hours later with surgical debridement and 
irrigation with 60mls of saline. After this treatment, in the three of the four non-control 
groups, a local antibiotic was inserted into the wound as per the allocation described 
above in Table 5.3. 
  
After fourteen days animals were euthanized: bone and implants were recovered and 
analysed for the presence of bacteria. The outcome measures were the presence 
and quantity of bacteria in the femur or attached to the implants (polyoxymethylene 
plate and K-wires). 
 
5.2.3 Local Antibiotics: Results 
Bacteria were recovered in all wounds in the control (no antibiotics received) and 
antibiotic-PMMA bead group. The group treated with antibiotic gel alone had 
significantly fewer animals with bacteria (p≤0.004) detectible in their wounds than 
these two groups, only half of the bone samples and 30% of the implant specimens 




Figure 5.3: Proportion of 20 samples from each treatment group of 10-animals with 
detectible bacteria at 14 days. Statistical differences by Fisher’s exact test are 
shown. *The antibiotic gel and antibiotic beads and gel group had a lower portion of 
the samples with bacteria that were recoverable than the other control and beads 
groups (p ≤ 0.0004). NS = no significant difference between adjacent groups. 
 
 
Antibiotic gel was significantly superior to antibiotic-PMMA beads at reducing 
bacteria on both the bone (p=0.001) and the implant samples (p=0.004) as shown in 
Table 5.4 below.  
 
Comparison Mann-Whitney Test Fisher’s 
test Group 1 Group 2 Bone Implant 
Gel Beads 0.001 0.004 <0.001 
Gel Beads/Gel 0.310 0.820 1.00 
Gel Control <0.001 <0.001 <0.001 
Beads Beads/Gel 0.001 0.007 0.001 
Beads Control 0.070 0.820 1.0000 
Beads/Gel Control <0.001 0.002 <0.001 
 
Table 5.4: P-value for comparison of groups by quantitative cultures of recovered 
bacteria from bone and implant samples (Mann-Whitney test) and presence or 

























































Interestingly, there was no difference in the quantity of bacteria from the wounds of 
those treated with antibiotic-PMMA beads and those animals in the control group that 
received no treatment, with respect to either bone (p=0.07) or implant samples 
(p=0.82), as shown in Figure 5.4. The addition of antibiotic-PMMA beads to antibiotic 
gel did not reduce bacterial quantities when compared to gel alone (p>0.3).  
 
 
Figure 5.4: Mean quantity of bacteria recovered from bone and implants from 
different treatment groups of ten animals. Error bars show standard error of the mean 
(SEM). Statistical differences between quantities of bacteria recovered from bone 
samples calculated by Mann-Whitney analysis are shown.   
 
 
5.3  Local Bismuth Thiol Gels with Systemic Antibiotics  
Bacterial persistence in spite of standard treatment with systemic antibiotics is 
believed to be at least in part due to the ability of bacteria in vivo to form an adherent 
biofilm19. Biofilms are formed when bacteria adhere to a surface such as a surgical 
implant or bone, and they secrete an extracellular polymeric substance which acts 
both as a protective barrier and as a medium for intercellular signaling20. Compared 
to planktonic bacteria, those in biofilms are much more resistant to treatment with 
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antibiotics and can survive exposure to concentrations of antibiotics many times 
greater than are toxic to planktonic bacteria20. Clinically, biofilms persist in 
musculoskeletal infection despite prolonged antibiotic treatment21. 
 
Compounds made from the chemical element bismuth have been used for centuries 
in wound dressings22 despite their relatively low antibacterial activity23 and potential 
for toxicity24. Bismuth was used extensively in the First World War to pack heavily 
contaminated open fracture wounds in the form of bismuth iodoform paraffin paste 
(BIPP), a paste made from bismuth subnitrate combined with iodoform and liquid 
paraffin. Its mechanism of action was not understood, but it was regarded as an 
effective treatment of infection with no local toxicity and only occasional systemic 
toxicity25. 
 
When bismuth is chelated with thiol compounds, the antibacterial effect is enhanced 
and mammalian toxicity is reduced26. Bismuth thiols (BTs) have been shown in 
preclinical studies to inhibit bacterial biofilm formation and adherence to surfaces27,28.  
 
When used in combination with antibiotics, BTs have been shown to significantly 
reduce the antibiotic concentrations required to inhibit Gram-positive and Gram-
negative bacteria, and in some cases synergize with certain specific antibiotics 
including tobramycin29. BTs, including MB-8-2 and MB-11, have also shown in vitro 
efficacy against MRSA and Pseudomonas aeruginosa biofilms when used alone or in 
combination with antibiotics30.  
 
The following study tested the hypothesis that combining BTs with systemic 
antibiotics will result in more effective reduction in rates of infection in an animal 
model of contaminated open fracture than systemic antibiotics alone. 
 
5.3.1 Bismuth Thiols: Formulations 
Three BT compounds were selected on the basis of their antimicrobial and antibiofilm 
activity,28,30: BisEDT (Bismuth-1,2-ethanedithiol), MB-8-2 (Bismuth-2,3-butanedithiol, 
2-mercaptopyridine N-oxide), and MB-11(Bismuth-1,2-ethanedithiol, 2-
mercaptopyridine N-oxide).  
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Hydrogel formulations of three different BTs were prepared in 50g lots, with each BT 
at 5mg/ml for the phase 1 study and MB-8-2 at 0.01, 0.1 and 1.0 mg/ml for the phase 
2 study as follows. A surfactant mixture was prepared by mixing 12.5g of 
polypropylene glycol NF, 250mg polysorbate-20 NF (Tween 20), and 50mg methyl 
paraben NF in a glass beaker. The mixture was heated to 70 oC in a water bath with 
periodic stirring until completely dissolved. BT powder (0.5, 5, or 50mg of Bis EDT, 
MB-8-2, or MB-11) was added to the surfactant mixture, stirred, and sonicated in a 
fume hood using an ultrasound indenter for 45 to 60 seconds.  
 
Immediately after sonication, 20g of hot (60° - 65 °C) purified water was added with 
mixing. In parallel, 150mg of xanthan gum (Kelco K9B310), 100mg of Ultrez 10 
(carbopol NF), and 2.5g of glycerin were stirred together in a separate glass vessel 
until a homogenous paste suspension was formed, then 14.24g of hot (60° to-65 °C) 
purified water was added and continuously mixed until the polymers were fully 
hydrated. The hydrated polymer suspension was combined with the BT surfactant 
mixture, stirred with a spatula to blend, and then mixed using a high-shear mixer 
(IKA-12) at high speed to form a gel. The beaker was then covered and sonicated 
using an ultrasonic bath to eliminate air bubbles in the gel. The pH of the gel was 
adjusted to 5.0 to 6.0 by adding 200mg 1N sodium hydroxide (NaOH) followed by 
mixing with a spatula and then with a high-shear mixer (IKA-12) at high speed. 
Before use, the BT gel was allowed to stand for 24 to 48 hours at room temperature 
to eliminate any additional air bubbles; gels were not sterilized before use as the very 
broad-spectrum antimicrobial activity of the BTs was thought to prevent any microbial 
growth in the gels. 
 
 
5.3.2 Bismuth Thiols: Study Groups and Methods 
The model described in Chapter Three and above in Section 5.1.1 was used both 
with, and without, the 7-doses of 5mg/Kg of Cefazolin described in Section 3.6. As 
previously described, the outcome measure was the presence of bacteria in bone or 
on implants retrieved from animals 14 days after ‘injury’ and treatment. 
 
There were two phases of the study. In the first phase, three different BT compounds 
at a single concentration were evaluated both in isolation and in combination with 
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systemic antibiotics. The second phase evaluated one of the compounds at three 
different concentrations.  
 
For Phase One of the study, each of the study groups of ten animals were inoculated 
with 1 × 105 CFUs of the Xen 36 strain of S. aureus. Without treatment this would 
result in a 100% infection rate.  
 
Six hours after ‘injury’ and ‘contamination’, the animals were treated with surgical 
excision of contamination and irrigation with 60mls of saline. After this, 1ml of BT-
hydrogel (containing 5mg of BT) was placed into the wound. Each compound was 
tested for efficacy against bacteria both individually and in combination with systemic 
antibiotics. 
 
Based on the results of Phase One, a single compound was selected for further 









Antibiotics Bismuth Thiol 
Phase 1 
1 10 Y Nil 
2 10 N 5 mg Bis-EDT 
3 10 N 5 mg MB-8-2 
4 10 N 5 mg MB-11 
5 10 Y 5 mg Bis-EDT 
6 10 Y 5 mg MB-8-2 
7 10 Y 5 mg MB-11 
Phase 2 
8 10 Y 0.5 mg MB-8-2 
9 10 Y 0.05 mg MB-8-2 
10 10 Y 0.005 mg MB-8-2 
Table 5.5: Study groups for Phase 1 and 2 of the study. ‘Antibiotics’ comprised of a 
regime of 5 mg/kg of cefazolin subcutaneously with the initial dose of antibiotic six 
hours after injury and continued every 12 hours thereafter for three days (seven 
identical doses in total). 
 
 
5.3.3 Bismuth Thiols: Results 
Across all groups treated with BTs at the initial concentration (5 mg/wound = 12.5 
mg/kg); local toxicity with wound breakdown was observed with MB-8-2 and MB-11 
and was present to a notably lesser extent with BisEDT.  
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Though apparently more locally toxic, MB-8-2 and MB-11 both demonstrated higher 
antibacterial activity than did BisEDT at this dose. Bacteria were detectable in all 
animals treated with BT alone and 60% of those treated with only systemic 
antibiotics. Animals treated with both systemic antibiotics and BTs did not have a 
significantly lower infection rate compared to those treated with systemic antibiotics 




Figure 5.5: Phase 1 results showing the proportion of 20 samples from each 
treatment group of ten animals with detectible bacteria at 14 days after treatment with 
three different BT formulations with and without cefazolin. No significant difference 
between groups was noted by Fishers exact test. 
 
 
However, animals treated with antibiotics alone had significantly more bacteria in 
their wounds than those treated with systemic antibiotics plus MB-8-2 (p = 0.031) or 





Figure 5.6: Phase 1 results showing mean bacterial quantification results from each 
treatment group of 10-animals treated with three different BT formulations with and 
without cefazolin in Colony Forming Units per gram (CFUs/g). Error bars show 
standard error of the mean (SEM). Differences between the control group and the 
MB-8-2 and MB-11 according to Mann-Whitney analysis are shown. 
 
 
MB-8-2 was subjectively assessed to cause less local tissue toxicity than MB-11 
while demonstrating more potent antibacterial activity than BisEDT. Accordingly, it 
was selected for further study in Phase 2. As shown in Table 5.5 above, MB-8-2 was 
tested in a further three groups at reduced dosages: 0.5mg, 0.05mg and 0.005 mg: 
all groups also received systemic antibiotics. 
 
A dose of 0.05 mg of MB-8-2 combined with systemic antibiotics resulted in a 
significantly lower infection rate (p = 0.0057) and bacterial quantification load (p < 





Figure 5.7: Phase 2 results showing the proportion of sample types from each 
treatment group of ten animals treated with reducing doses of MB-8-2 combined with 
a cefazolin treatment. Twenty samples were recovered from each group: 10 bone 
and 10 implants, thus giving a maximum of 20 positive samples for each group. 
Significance by Fisher’s exact test is shown. 
 
 
Figure 5.8: Phase 2 results showing the proportion of sample types from each 
treatment group of 10 animals treated with reducing doses of MB-8-2 combined with 
a cefazolin treatment. Twenty samples were recovered from each group: 10 bone 
and 10 implants, thus giving a maximum of 20 positive samples for each group. 
Significance by Fisher’s exact test is shown. 
94 
No systemic or local toxic effects were observed at this concentration and there was 
no gel residue.  The higher and lower doses (0.5 and 0.005 mg) were not as effective 
at reducing bacteria. 
5.4 Conclusions 
The results of the three studies presented in this chapter allow certain conclusions to 
be drawn. Firstly, these results are consistent with previous clinical and animal 
studies that have failed to demonstrate that any antiseptic solutions are superior to 
saline for reducing infection in open fractures. Secondly, there are more effective 
vehicles for delivering local antibiotics into open fracture wounds than the current 
clinical standard of PMMA beads. Finally, the findings presented demonstrate the 
proof of the concept that bismuth thiols exert a synergistic effect with antibiotics, 
potentially identifying a new class of treatment of infection after open fracture. 
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Chapter Six:  Discussion 
 
6.0 Introduction 
In Chapter One at the start of this thesis I set out the gaps in our current 
understanding of the nature of combat casualties, and particularly those who sustain 
open fractures. Specifically, the following four questions were identified as 
outstanding: 
 
1. Has survival after combat injury improved and are we  measuring it 
accurately? 
2. How common is infection after open combat fractures, and what are the 
consequences? 
3. How does the timing of surgical and antibiotic treatment of open fractures 
affect infection? 
4. Are there novel treatments that might reduce infection in open fractures?  
 
In Chapters Two to Five a series of studies were described that aimed to answer 
each of these questions. In this final chapter, the findings of these studies will be 
reviewed and examined further in the context of both the published literature and the 
strengths and limitations of the approaches I have used. 
 
 
6.1 Has survival after combat injury improved, and are we measuring it 
accurately? 
The original rationale for exploring this question was to examine the premise that 
improvements in trauma care have led to a cohort of casualties surviving with more 
complex extremity wounds than have previously been encountered1.  
 
The second part of the question: i.e. ‘Are we measuring it [survival] accurately?’ has 
wider significance beyond this work. To improve the performance of a complex 
system such as combat casualty care, the ability to accurately measure survival and 
therefore the effect of any new intervention, permits the identification of more 




6.1.1 The probability of survival 
In Chapter One I described how registries of traumatically injured patients evolved in 
both the civilian and military sectors in an attempt to measure system performance. 
In order to do this, for each patient included in the registry, a Probability of Survival 
(Ps) is determined. If the Ps is greater than 0.5 that individual is expected to survive: 
if it is below 0.5, they are expected to die from their injuries. A patient who survives 
with a Ps<0.5 is termed an unexpected survivor, while a patient who dies with a 
Ps>0.5 is referred to as an unexpected fatality. The greater the ratio of unexpected 
survivors to unexpected fatalities, the better the performance of the trauma system. 
 
In the civilian setting the UK Trauma Audit and Research Network (TARN) and the 
US National Trauma Data Bank (NTDB) use probability of survival methodology to 
compare survival at individual hospitals to that of the overall system. This allows the 
performance of the hospital relative to all others in the system to be established. 
 
The US NTDB uses the TRISS methodology to calculate a patient’s Ps (described in 
detail in Chapter Two). The UK TARN registry initially used TRISS then transitioned 
to a methodology devised specifically for the UK to account for the more elderly 
population, and the preponderance for blunt mechanisms of injury of traumatically 
injured patients in the UK2. 
 
The military trauma registries in the UK and the US both use TRISS methodology. In 
the military combat casualty care system, a single casualty is likely to receive 
treatment in several facilities as they are sequentially moved away from their point of 
wounding and back to their home country. It is therefore not possible to isolate the 
performance of a single ‘hospital’ or facility as described for civilian trauma 
healthcare. Instead the number of unexpected survivors has been cited as a 
measure of the performance of the UK Defence Medical Service’s Combat Casualty 
Care system. The 2010 National Audit Office report on this subject stated: 
 
‘The Department’s and the NHS’ methodology for calculating unexpected survivors 
differs and so a direct comparison is not easy, but ostensibly its unexpected survivor 
rate compares favourably with that achieved by the best NHS hospitals.’ 
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It is important to note that the numbers of unexpected fatalities were not presented in 
this report; arguably one figure without the other is meaningless. This omission is not 
necessarily for nefarious reasons. It would cause huge distress to bereaved families 
for the term unexpected fatality to be used as it implies ‘unnecessary’ or ‘avoidable’ 
death, which is inaccurate. While the TRISS methodology is accurate at predicting 
survival across a population of trauma patients, it is an imperfect tool for individuals, 
failing to take into account specific circumstances e.g. pre-existing co-morbidities or 
medications.  
 
However, in the course of this work I determined that the UK military trauma registry, 
the Joint Theatre Trauma Registry (JTTR), was using the original TRISS coefficients, 
meaning that the standard of survival was based on data from the US gathered in the 
1970s and 1980s as part of the Major Trauma Outcomes Study. Therefore, not only 
was the probability of survival not being used as intended as a ratio of unexpected 
survivors to unexpected fatalities, but the expectation of survival was decades out of 
date. 
 
As a result of this I proceeded to determine whether combat casualty survival 
improved over the 14-years of the conflicts using the New Injury Severity Score 
(NISS), with the intention to return to the TRISS methodology to see whether this 
could be improved. 
 
6.1.2 Using New Injury Severity Score to measure survival 
As described in Chapter Two, each of the cases in the JTTR has been coded with 
the New Injury Severity Score (NISS) giving a quantification of injury severity 
according to anatomic scoring. For each calendar year, there was a different number 
of heterogeneous cases precluding direct comparison of survival rates. In order to 
establish the relationship between a non-parametrically distributed independent 
variable (NISS) and the dichotomous dependent variable (mortality), the use of 
logistic regression modelling was the preferred technique. 
 
In order to ensure that the model was expertly constructed and tested, a specialist 
biostatistician at the Birmingham University Clinical Trials unit, Dr Jon Bishop, was 
approached. Dr Bishop confirmed that the use of a logistic regression model was an 
appropriate technique and developed a model using the R statistical suite. Within 
	 100 
each year it was clear that there would not be a NISS ‘threshold’ of survival i.e. a 
level above which all casualties survived and below which they all died. Therefore the 
relationship between the NISS and survival was not linear and restricted cubic 
splines were used in the development of models to ‘smooth’ the data3.  
 
In order to select the most appropriate model, the choice of methodology was 
between the use of the Akaike Information Criterion (AIC)4 or a Bayesian information 
criterion (BIC)5. Both techniques would likely produce similar result, however given 
that none of the postulated models could be absolutely ‘true’, the use of AIC was 
judged to be theoretically most appropriate6. The goodness of fit of the selected 
model was assessed by using the le Cessie-Van Houwelingen-Copas-Hosmer 
goodness-of-fit test7. 
 
As described in Chapter Two the model finally selected demonstrated that the NISS 
associated with an observed Ps of 0.5 increased every year from 32 in 2003 to 60 in 
2012, and that this improvement was highly significant. 
 
We believe that this analysis was the first time that survival improvement over the 
course of a conflict has been reliably demonstrated. This analysis was reported in the 
lay-media as shown in Figure 6.1 below: 
 
 
Figure 6.1: Article from Daily Telegraph 4th June 2015 regarding the publication of 
the NISS survival analysis earlier that year in the Journal of Trauma. 
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It is important to acknowledge that although all of the techniques used in our analysis 
have been used extensively in other fields of medicine, this appeared to be the first 
time they had been applied to combat casualty data. The use of sophisticated logistic 
modelling is considerably more complex than traditional attempts to demonstrate 
improved survival e.g. Case-Fatality Rate, as detailed in Chapter One. 
 
A disadvantage of this approach is that it requires a reasonably sized data set, i.e. a 
large number of casualties. In military operations with low numbers of casualties e.g. 
peace-keeping roles, a similar analysis is unlikely to be possible. Furthermore, the 
NISS of fatalities as well as survivors needs to be recorded for the analysis described 
to be possible. This means that comparing survival rates across other military 
systems is challenging (e.g. the US JTTR has incomplete NISS data on fatalities), 
and similar issues exist with records of historic conflicts. This last point was illustrated 
when, in unrelated work, I tried to compare survival during the Falklands conflict with 
that in Afghanistan 35 years later8. Due to the lack of NISS data on fatalities in the 
historic group, the only way to indicate likely differences in survival between the two 
conflicts was to identify the survival of more casualties with more severe injuries in 
the later conflict. 
 
However, in the case of the recent UK military experience in Iraq and Afghanistan the 
JTTR does provide sufficient data for this analysis. The thorough examination of this 
analysis, described above and in Chapter Two, gives me a high level of confidence 
that this methodological approach has been proved to accurately describe the 
relationship between NISS and survival over the study period. 
 
 
6.1.3 Developing Trauma Injury Severity Score coefficients to predict survival 
after contemporary combat injury 
As previously stated, NISS is based on the Abbreviated Injury Scale (AIS)9, an 
anatomic description of injuries which fails to account for differences in physiology. 
Combat casualties are typically young men with a median age of 2510. By definition, 
individuals deploying on military service are fit, free from active co-morbidities and 
have completed a rigorous pre-deployment training process. It is feasible that 
measuring military trauma system performance using a scoring system based purely 
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on an anatomic description of injuries, and established from civilian registry data with 
older, less healthy individuals, is likely to exaggerate performance.  
 
As mentioned previously, it was my initial intention to use the TRISS methodology to 
generate a Ps for each patient based on their injuries and physiological status and 
taking into account the age of the casualties. This would also be consistent with the 
civilian UK and US approach to measuring trauma system performance. However, as 
stated in Chapter Two the TRISS values in the JTTR were based on out-dated 
coefficients and without any indication of whether casualties injured by explosive 
weapons were coded as ‘penetrating’ or ‘blunt’. 
 
By the stage that the NISS based phase of the analysis had been completed, a 
further 2-years of JTTR data was available bringing the study period to 12-years 
(2003-14). As detailed in Chapter Two, only those casualties injured by gunshot 
wounds (GSW) or from explosive weapons were included in this re-analysis.  
 
In order to ‘reverse-engineer’ two sets of TRISS coefficients that reflect contemporary 
survival rates, multi-variant regression would be required, in the same way that this 
method was used to derive the original TRISS coefficients. I once again requested 
that Dr Jon Bishop assist me in constructing the model, and the more complicated 
task of validating the coefficients. 
 
New coefficients were derived as described in Chapter Two, however validating 
them was a challenge. Unsurprisingly the Receiver-Operator Curve (ROC) analysis 
of the performance of the revised coefficients in predicting outcome in the data set 
from which they were derived was excellent. However, this performance with the 
original data set does not necessarily assure similar performance in a different but 
comparable dataset e.g. from a peer-military such as the US, or from a future UK 
conflict.  
 
There were a number of solutions to the problem of validation. Firstly, given that the 
US had been involved in the same conflicts as the UK military over a similar period, 
using their Joint Theatre Trauma Registry as a comparable dataset presented an 
option for possible external validation. In order to access this, in 2015 I instigated a 
discussion which included the UK Defence Professor of Military Surgery, Surg Capt 
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Rory Rickard, and the then head of the US JTTR. My aim was to agree a 
memorandum of understanding between the UK Ministry of Defence and the US 
Department of Defence for a collaborative team to be established in order to jointly 
evaluate the newly developed TRISS coefficients using a sample dataset from the 
US JTTR. 
 
This goal was never achieved: it became apparent during discussions that the US 
JTTR data on fatalities was far less complete than the UK’s and that a majority of US 
fatalities did not have NISS data recorded. A further cause of sensitivity was the 
possibility that this process would lead to a direct comparison between the two 
countries’ combat casualty care systems’ performance. Discussions failed to achieve 
agreement. For obvious reasons a dataset from a civilian trauma registry would not 
be suitable to validate combat TRISS coefficients. I therefore concluded that 
validation with an external data set was not possible. 
 
Having decided that the new TRISS Coefficients would need to be internally 
validated, I approached Dr Jon Bishop for expert advice on this area. 
 
The main techniques used for internal validation (with respect to discriminative ability, 
calibration and overall accuracy) for logistic regression models are split-sampling (10-
fold/cross validation) and bootstrapping. Split-sampling was considered, but given the 
limited size of the original data set, dividing this into a derivation set and a validation 
set would likely significantly reduce the accuracy of the coefficients that could be 
derived originally.  Bootstrapping is a development of the split sampling approach 
where the sample is ‘replaced’ within the original dataset. Bootstrapping has been 
demonstrated as a superior technique for assessing internal validation, and was 
therefore selected for this purpose in this study11. 
 
While external validation with a second, comparable data set would be ideal, the 
internal validation and the performance of the new TRISS coefficients leads me to be 
highly confident that the new coefficients are precise and accurate in predicting the 




6.1.4 Using contemporary Trauma Injury Severity Score coefficients to predict 
survival after contemporary combat injury 
When the new TRISS coefficients were compared to the original ones, there was 
only a very modest difference in the Receiver-Operator Curves as shown in Figures 
2.4 and 2.5. This might lead to the conclusion that developing newer TRISS 
coefficients is unnecessary as the improvements in accuracy are extremely marginal. 
However, it is worth noting that when the new TRISS coefficients are used to model 
trends in survival using the same modelling techniques previously described in 
conjunction with NISS, the results are very different. 
 
The plot in Figure 2.6 shows that over the course of the conflict survival improves to 
the point where the original TRISS coefficients are unable to accurately predict 
survival. However, the new TRISS coefficient allows the model to work as one would 
anticipate: an improved performance over the initial years of the conflict until a 
plateau of performance is reached. This plateau occurs around the level at which a 
Ps of 0.5 is associated with 50% survival equipoise i.e. exactly how TRISS should 
perform. 
 
Even if the performance of the old and new TRISS coefficients was not as stark in 
practice, it would still be important to use them. The performance of the UK Defence 
Medical Service’s combat casualty care systems is measured based on statistics 
gathered by the Ministry of Defence (MOD) administrative agency, Defence 
Statistics. In effect, the MoD is measuring its own performance, and under such 
circumstances it is important to be able to demonstrate that every effort is made to 
ensure that that this process is rigorous and accurate. For that reason, it would be 
preferable for the MOD to use updated and mechanism-specific TRISS coefficients to 
measure the performance of its combat casualty care system. 
 
From this I draw two conclusions, firstly, using two different measures of injury 
severity, NISS and TRISS, survival after combat injury improved over the course of 
the conflict. Secondly, that the use of a modified TRISS will allow accurate 
measurement of combat casualty care, even at performance levels at which the 




6.1.5 Future work in measuring survival after combat injury 
Other investigators have attempted to improve the methodology for measuring 
survival in the area, by adapting purely anatomic injury scoring systems for military 
casualties12. However, systems that incorporate both the anatomical injury and the 
physiological response to that injury have theoretical and practical advantages over 
purely anatomic based systems, and are favoured by the UK MoD13, TARN2 and the 
US National Trauma Data Bank14. In practice the modified military TRISS model 
developed in this study significantly outperforms recently described military anatomic 
systems12. 
 
Some researchers have attempted to use Bayesian networks to improve the ability to 
model survival after combat injury. This is a very attractive approach particularly for 
handling data from registries, as Bayesian networks are capable at handling missing 
data, an inherent feature of registries. However, so far efforts to use Bayesian 
networks for this purpose have been less precise than the improved TRISS 
methodology described above15. 
 
It is worth considering whether ‘survival’ is the only standard by which the 
performance of combat casualty care systems should be measured. Mortality is 
clearly important, and is an objective and simple outcome, however other metrics are 
important and feasible.  
 
Patient Reported Outcome Measures (PROMs) and military specific outcomes such 
as Return to Duty (RTD) and completion of fitness tests, could be used as measures 
of recovery. 
 
PROMs are increasingly recognised as an important approach for judging the 
effectiveness of healthcare interventions16. In separate studies unrelated to this 
thesis I have used PROMs (Short Form-3617) to determine whether patients have a 
better quality of life with amputation or limb reconstruction following combat 
injury18,19. It would be feasible to incorporate follow-up with PROMs into the UK 
JTTR, providing a measure of generalised rehabilitation rather than just survival. 
Given that many cases in JTTR have very minor injuries, for practical purposes it 
would be appropriate only to gather PROMs on those with injuries more severe than 
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a given threshold e.g. NISS≥15, and at specific points following injury e.g. twelve and 
24 months. 
 
In addition to PROMs it is also possible to gather outcome measures unique to the 
military. After traumatic injury, service personnel will be placed into a medical 
category: fully fit with no restrictions; medically downgraded with specific restrictions 
e.g. no load carrying; or medically discharged. An individual’s return to duty following 
injury is recorded on the Joint Personnel Administration (JPA) system, and could be 
incorporated into the JTTR as an outcome measure. Return to duty status is related 
to whether an individual passed their annual fitness test after their injury and is 
likewise recorded on their JPA record. 
 
As survival reaches the limits of human physiology measuring improvements in 
combat casualty care system performance becomes more challenging. The addition 
of these outcome measures for quantifying the recovery would allow future changes 
in performance to be detected. 
 
 
6.2 How common is infection after open combat fractures, and what are the 
consequences? 
Having established that survival had improved over the course of the Afghanistan 
and Iraq conflicts, this phase of study was focused on defining the problem of open 
combat fractures in these survivors.  
 
In order to address this question, it was divided into components which were 
examined separately: 
 
1. How common are open fractures after combat injury? 
2. How many combat injuries are complicated by infection? 
3. What organisms are responsible for infections? 
4. Is infection associated with a poorer outcome? 
 
This phase of the study relied on identifying cases through the JTTR registry and 
then correlating them with clinical records. With any research based on registry data 
errors and inaccuracies in initial coding will be reflected in the results and 
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conclusions. It is believed that the quality of coding may have been weaker in the first 
three years (2003-2006), and coding of lesser injuries may have been incomplete. 
Similarly, it is reasonable to speculate that in extremely severely injured casualties 
some minor injuries might be overlooked. 
 
6.2.1 How common are open fractures after combat injury? 
As detailed in Chapter Two around 75% of injured survivors have an extremity 
injury: approximately 5% of these involved an open tibia fracture, the most frequently 
open fractured bone. 
 
The relative frequency of open tibia fractures represents a particular challenge as it is 
regarded by orthopaedic surgeons as particularly prone to infection and healing 
problems due to its poor soft tissue envelope20. 
 
6.2.2 How many combat injuries are complicated by infection? 
Having defined the number of open fractures in general and the frequency of open 
tibia fractures in particular, the next question was how many of them are complicated 
by infection? 
 
Defining surgical site infection after elective surgery can be challenging21: this is 
certainly true after open fractures and especially true of those sustained on the 
battlefield. Combat open fractures are, by definition, contaminated to some degree 
with microorganisms. There is likely to be a spectrum from universal contamination to 
colonisation and then infection.  
 
All combat open fractures were treated with antibiotics, which were typically 
continued beyond the 72 hours recommended by the BAPRAS-BOA national 
standards22. Prolonged antibiotic therapy was often used prophylactically because of 
the heavy contamination frequently seen in these injuries, despite the recognised 
lack of evidence for this strategy23,24. 
 
Given this potentially confusing clinical picture of contaminated, complex open 
fracture wounds already receiving prolonged antibiotic treatment, determining which 
were infected was challenging, particularly as this was to be done from a 
retrospective review of clinical notes. To avoid ambiguity, I decided that the standard 
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of infection in this study should be that the treating consultant surgeon decides that 
there is a clinical diagnosis of infection requiring surgical treatment. 
 
While this is still a subjective definition, much of clinical healthcare is subjective and 
based on judgment. I believed that using a definition with a ‘threshold’ i.e. surgical 
treatment, makes it more specific, but at the risk of reducing the sensitivity. This 
would mean that wound infections that could be successfully treated by resuming 
antibiotic treatment were not included as ‘infections’. However, this also avoids Type 
I error of over-diagnosis of infection in the presence of e.g. inflammation or 
haematoma.  
 
This definition of infection was used by Burns et al. in their case series of US military 
personnel injured on operations in Iraq an Afghanistan. The findings of their study 
were strikingly similar to mine; they reported an infection rate of 27% in 213 open 
tibia fractures compared to 23% in 93 fractures in this work25. 
 
The largest prospective study of lower extremity trauma in the civilian literature is the 
Lower Extremity Assessment Project (LEAP). This work did not clearly define 
infection either in the protocol26 or published results27. However, they do report that 
22% of 541 cases had wound infections (undefined) that required surgical treatment. 
It is important to note that the LEAP study included a range of severe lower-limb 
threatening injuries, and not just open tibia fractures. 
 
Some researchers have sought to define infection as the presence of detectable 
bacteria in microbiological samples taken from the wound. In their series of 35 open 
tibia fractures in US service personnel injured in Iraq and Afghanistan, Johnson et al. 
reported an infection rate of 77%28.   
 
As stated previously, the presence of detectable bacteria may not necessarily be 
pathological, as all of these wounds are contaminated and all open wounds are likely 
to be colonised to some degree with bacteria. It is interesting to note that the two 
studies (LEAP and Burns et al.)  that used a similar clinical definition of infection 
report an infection rate of around 20%, consistent with my findings, substantially 




6.2.3 What organisms are responsible for infections? 
In the clinical care of the patients with open tibia fractures described in this work, 
multiple tissue samples rather than wound swabs were taken at each surgical 
episode. In cases meeting the definition of infection, Dr Debbie Mortiboy, the clinical 
consultant microbiologist at University Hospitals Birmingham responsible for 
processing these samples, was contacted and asked to confirm the causative 
organisms in each case, based on contemporaneous results.  
 
While I would readily acknowledge that multiple species were detectable in many of 
the infected wounds, in the experience of the clinicians treating these injuries a single 
microorganism typically predominated in clinically significant infection, possibly due 
to the background of extensive antibiotic use in these patients29. It is arguably an 
over-simplification to focus on a single organism in every case, but I regard this as a 
pragmatic approach in the clinical setting. 
 
The findings detailed in Chapter Two show that the causative pathogens in UK 
service personnel with open tibia fractures were overwhelmingly S. aureus species, 
responsible for 60% of infections. In the series described by Burns et al., S. aureus 
was responsible for only 35% of infections, but with another Staphylococcus species, 
S. epidermidis, responsible for a further 20%. This is in stark difference to the series 
reported by Johnson et al., which reported that S. aureus species were responsible 
for only 9% of open tibia infections, with gram-negative species responsible for the 
majority. 
 
My interpretation of the disparity between the studies based on a clinical diagnosis 
i.e. my study and the Burns series25 and Johnson’s microbiological defined series28 is 
that gram-negative bacteria may colonise many wounds without necessarily causing 
clinically important infection. Furthermore, it appears that gram-positive 
Staphylococcus species, specifically S. aureus, cause the majority of clinically 
relevant infection following open fracture. 
 
6.2.4 Is infection associated with a poorer outcome? 
In Chapter Two, the question of whether infection was associated with a poor 
outcome was examined in a series of 57 open tibia fractures30. The premise of this 
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phase of the work was to determine whether infection detrimentally affected efforts at 
surgical reconstruction. Therefore, the outcome measures and study period were 
selected accordingly.  
 
Twelve-month follow-up was used in this study, as although the acute care of 
casualties occurs at one institution, this military population live in all regions of the 
UK. At their request, ongoing care may be transferred to hospitals closer to their 
home. As a result, there is a significant drop in the proportion of patients being 
followed up at this institution beyond the twelve month point. It is likely that if the 
follow-up period was longer, a greater proportion of poor outcomes would be 
detected. However, the authors regard the 91% follow-up of all fractures as sufficient 
for conclusions to be drawn. It was also reasonable to predict that clinically relevant 
problems such as infection would manifest within this twelve month period 
 
The choice of outcome measures also reflected the premise of this phase of the 
study. A surgical outcome i.e. revision surgery (including amputation) was used. This 
was in preference to choosing a patient reported outcome measure (PROM), as the 
effect of infection would likely be confounded by coexisting injuries.  
 
However, while PROMS were not directly measured in my study, they were used by 
the LEAP study, which demonstrated the detrimental effect of unplanned revision 
surgery on the Sickness Injury Profile PROM31. 
 
The statistical analysis approach used was simplistic-the relationship between each 
of the dependant variables and the independent variable was examined separately. 
An alternative approach would have been developing a logistic regression model, this 
would have provided greater detail about the relationship between the variables and 
the outcome. However, for simplicity a direct comparison was used together with 
Bonferonni correction to allow for multiple comparisons. 
 
It is important to acknowledge that a retrospective examination of this type can only 




6.3 How does the timing of surgical and antibiotic treatment of open fractures 
affect infection? 
The studies in Chapter Two defined and characterised the nature of the problem of 
infection in open fractures, thereby answering the first two questions laid out in 
Chapter One. 
 
In order to answer the second two questions laid out in Chapter One, I decided that 
an animal model would be necessary to examine the issues involved. The rationale 
behind the choice of rodent model was outlined in Chapter Three, as was the need 
to refine and evolve the model to better address the specified questions. 
 
6.3.1. Model development: bacterial inoculation 
The early experience of this model in the US Army Institute for Surgical Research 
used an inoculant of 1×105 Colony Forming Units (CFUs). When this was treated with 
irrigation and debridement at six hours post-inoculation, robust infection was 
detectable in all animals necessitating differentiation in the degree of contamination 
using bacterial quantification32. When I joined the laboratory, I identified the dangers 
of this approach: when the bacterial contamination is this stringent, the effect of 
treatments that produce anything less than a massive effect on bacterial levels will 
not be detected, leading to a Type II error. Additionally, a treatment that actually 
exerted a negative influence on infection i.e. increased infection rates, might not be 
detected. Finally, in an under-contaminated model where none of the wounds would 
go on to infection, a positive treatment effect might not be detected. These examples 
show the importance of avoiding a floor or ceiling effect.  
 
The results of this study establish the bacterial inoculation associated with a 50% 
infection rate, therefore refining this model for the follow-on studies described 
below33. It also established a dichotomous ‘infected or not’ measure to be used 




6.3.2 Model development: systemic antibiotics 
In clinical practice, antibiotics may be delivered locally as well as systemically34. In 
fact this combined delivery approach may represent the area of treatment with the 
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most potential for development. The most common local antibiotic vehicle remains 
antibiotic-loaded polymethylmethacrylate (PMMA) ‘bone cement’35. Prior to my 
arrival, the US Army Institute of Surgical Research had previously published work on 
the introduction of antibiotic PMMA beads into their open-fracture model32.  
 
This model-development study established that animals inoculated with 105 CFU of 
bacteria and then surgically treated at six hours post-inoculation had an infection rate 
of approximately 50% when treated with 5mg/kg of systemic cephazolin for three 
days. This enabled the model of infection to more closely mimic the regular clinical 
practice of concurrent treatment with systemic and local antibiotics. This then 
permitted the model to be used to investigate the relationship between infection and 
antibiotics delivered in a variety of different combinations and forms36. Furthermore, it 
allowed surgical treatment and antibiotic treatment to be initiated at different time 
points. This was an essential step in the model development in order for it to be used 
to accurately examine the relationship between the timing of treatment and 
infection37.  
 
Use of systemic antibiotics at a dosage that still results in 50% infection rates allows 
treatments that work synergistically with antibiotics to be tested, and avoids floor or 
ceiling effects in this modification of the basic model. 
 
6.3.3 Model development: interpretation of results 
The results of these model development studies had some common features. 
Specifically, there were groups in both studies in which either all or none of the 
animals were infected: when all of the animals were infected, bacterial levels were 
similarly high. Furthermore, in both studies there was a single group where the 
balance of antibiotic dose or bacterial inoculation resulted in an infection rate of 
approximately 50%. 
 
I interpreted these findings as representing a balanced ‘tipping point’ between pro- 
and anti-infective factors, which I represent graphically in the idealised sigmoid curve 




Figure 6.2: Idealised curve representing the ‘tipping point’, at which a host’s immune 
system is unable to eradicate infection and a group of animals in a study group will 
move from 0% infection to 100% infection with a small increase in pro-infective 




The sigmoid curve as shown above in Figure 6.2 is a common treatment effect 
across dose response studies. In a clinical scenario, a low level of contamination is 
easily managed by the casualty with an open fracture with no resultant infection; 
however, at a certain level of contamination (or other pre-infective factor e.g. tissue 
necrosis), a tipping point is reached above which bacterial multiplication overwhelms 
this host immunity and an infection occurs.  
 
Clinically, we may influence this outcome with a therapy that translates this situation 
to the left of the curve. If it moves the contamination off the steepest part of the 
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curve, it may mean that even a modest treatment effect creates a sufficiently different 
infection rate to reach significance. In the model, defining this ‘tipping point’ for initial 
contamination or bacterial dosage allows the maximum potential for demonstrating 
an effect, whether positive or negative, of an intervention group.  
 
The results of the model development studies in Chapter Three demonstrate the 
effect when the pro- and anti-infective variables are changed subtly to result in a 
significant effect on the proportion of animals with bacteria recoverable from their 
wounds. These results demonstrate this discrete ‘tipping point’ in the balance 
between pro- and anti-infective factors across multiple studies testing novel products 
and treatment strategies. They also demonstrate the importance of this to avoid floor 
or ceiling effects of tested interventions33,38. 
 
 
6.3.4 Model strengths and weaknesses 
The development of this model allowed it to be adapted to examine the questions 
described in Chapters Four and Five, and to be published in international journals 
e.g. Bone and Joint Journal38 and the Journal of Orthopaedic Trauma33,39,40. 
 
However, there are limits to the extent that findings from animal studies can be 
extrapolated to clinical practice or even trials due to obvious differences in scale, 
anatomy and physiology. The model used in this study mimics clinical practice but 
does not recreate the clinical reality of open fractures. Some key differences include 
the absence of significant soft tissue damage, a surgically created defect rather than 
fracture and a single surgical treatment. Furthermore, the immediate fixation and 
primary closure between injury with contamination and surgical treatment including 
debridement and irrigation clearly differs from clinical practice.  
 
I have previously argued in this chapter that the presence of bacteria is a measure of 
contamination or colonisation and is not necessarily analogous to infection. However 
in the animal studies I did equate the presence of detectable bacteria as equivalent 
to infection. This apparent contradiction was primarily to allow an objective and un-
ambiguous outcome measure for this animal study. Other studies have relied on 




Cephazolin was used in this model because cephalosporins are the recommended 
antibiotic option in open fractures20, and previous experience with cephazolin in 
similar animal models reduced the model development work required to design this 
study. I believe that since this model involves an organism known to be sensitive to 
the antibiotic used, the effects observed should be similar with different combinations 
of bacteria and antibiotic provided there is microbiological sensitivity.  
 
The choice of a S. aureus species is appropriate given this species was identified in 
Chapter Two as being responsible for the majority of tibia open fractures in UK 
service personnel. 
 
It is possible that the effects observed might be more pronounced with the 
intravenous route of administration of antibiotics typical in clinical practice rather than 
with oral ingestion or the subcutaneous route that was used in this model. These 
latter routes were chosen in this animal study to avoid the morbidity associated with 
repeated venepuncture in a small mammal.  
 
Within the limits of animal welfare and practicality of a cost-effective model use, I 
believe my results demonstrate the appropriateness of this model in answering the 
research questions for which it was used. 
 
 
6.3.5 The timing of surgical and antibiotic treatment of open fractures 
The first study examining the timing of wound debridement was originally based on 
an animal study involving 21 guinea pigs performed by Friedrich in 189843. The study 
found that animals with wounds debrided within six hours had no infection; this 
finding became the basis of the orthopaedic doctrine known as the ‘six hour rule’44.  
 
Further animal based research repeated these findings: Dhingra et al. in 1976 
demonstrated that a delay of debridement from two to four hours led to a significantly 
greater infection rate in soft tissue wounds45. Recently, Brown et al. used a rat model 
of contaminated open fracture to show that the quantity of bacteria in subsequent 
infection is proportional to the initial delay until surgical debridement32.  
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Most of the clinical evidence on the timing of initial surgery in open fractures comes 
from observational cohort studies. Results in these studies were analysed with either 
regression analysis or by directly comparing infection rates between ‘early’ and 
‘delayed’ cohorts.  
 
Studies using this methodology have reached divergent conclusions with a majority 
concluding that early surgery is of little benefit. Only three studies have identified a 
link between delayed surgery and infection: Kindsfater and Jonassen examined all 
Gustillo-Anderson46 (GA) Grade II and III open fractures of the tibia and found greater 
infection rates in fractures debrided more than five hours after injury compared to 
those debrided less than five hours after injury47. Kreder and Armstrong examined 
open tibia fractures in children and similarly found that surgery beyond six hours 
correlated to increased infection, but their results did not reach significance48. Jacob 
et al. examined US military casualties of the 1989 invasion of Panama and found a 
higher rate of infection in GA III fractures whose surgery was delayed until return to 
the US compared with those surgically treated rapidly in Panama49. 
 
Using a similar observational approach, Patzakis and Wilkins; Dellinger et al.; Bednar 
and Parikh, Skaggs et a.l, Harley et al., Khatod et al., Ashford et al., Spencer et al., 
Charalamous et al., Al Arabi et al., Reuss and Cole; and Al-Hilli and Salih, all found 
conversely that the risk of infection or non-union did not increase despite delayed 
debridement in patients who had received early systemic antibiotics22,50-61.  
 
A component of the LEAP study included a prospective observational study of 315 
patients with GA III open fractures of the tibia, foot and ankle, who received standard 
treatment including antibiotics. In a multi-variant regression analysis they also found 
that delay between injury and surgical debridement was not related to infection rate62. 
 
More recently in 2014 Hull et al., published a clinical study which used retrospective 
registry data on 459 open fractures63.  These researchers regarded delay to surgical 
treatment as a continuous variable and performed their analysis with a multi-variant 
regression model similar to the LEAP approach. Their results however were different, 
as they found that a significantly increased risk of infection for every hour of delay 
(odds ratio = 1.033: 95% confidence interval 1.01 to 1.057). 
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The opposing conclusions drawn by the animal studies and the majority of 
observational case series can be explained by their respective methodologies. 
Previous animal studies examining the timing of surgical debridement do not involve 
systemic antibiotic administration which may well make delaying surgery ‘safer’ with 
respect to infection.  
 
For obvious ethical reasons all clinical studies to date have been observational in 
nature and this means that the likely tendency of clinicians to prioritise the most 
heavily contaminated injuries for earlier surgical debridement potentially ‘balances’ 
late and early treatment arms. Early surgery groups in these studies may well contain 
a greater proportion of cases performed ‘out of hours’ by less experienced, on-call 
staff and consequently may have received sub-optimal treatment relative to those 
patients treated on scheduled trauma operating lists by consultant surgeons. 
 
Altemier et al. published the first experimental work on the effect of the timing of the 
antibiotics on wound infection in 1947. Their study considered the impact of timing of 
antibiotic administration on the survival of guinea pigs with wounds infected with C. 
perfringens. They demonstrated a significant deterioration in survival times when a 
regular intramuscular penicillin regime was initiated six-hours post injury compared to 
immediate post-injury administration64.  
 
Owen-Smith and Metheson showed that even with wound debridement at six hours, 
delaying antibiotics worsened survival in sheep with penetrating soft-tissue wounds 
contaminated with C. perfringens65. Reaching similar conclusions Mellor et al. used a 
porcine penetrating injury model to demonstrate that when the start of a three day 
course of benzylpenicillin was delayed from one to six hours post-injury, it was 
rendered ineffective in preventing infection66. 
 
Despite the early animal studies, clinical opinion remained divided on the benefit of 
‘prophylactic’ antibiotics. Two case series of open fractures published in the 1960s 
did not support the use of antibiotics at all until infection was suspected67,68. The 
issue of the use of prophylactic antibiotics was settled definitively in Patzakis, Harvey 
and Ilver’s 1974 randomized control trial of antibiotics in all types of open fracture. 
They demonstrated that those not treated with antibiotics had significantly greater 
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rates of infection compared to the group treated with a cephalosporin50. 
Unfortunately, the effect of timing of antibiotic administration was not evaluated.   
 
Two case series of military patients injured in separate conflicts provided a natural 
experiment on antibiotic timing: British servicemen in Borneo in 1963-65 were issued 
oral oxytetracylcine to take immediately if injured. Wound infection rates were lower 
than in casualties from the 1982 Falklands conflict with similar injuries who did not 
receive antibiotics until evacuated to a medical aid post. This difference was only 
observed in patients reaching surgery within six hours, and numbers were too small 
to reach significance69,70.  
 
In the case of the Falklands conflict, seven of the nine cases of wound infection did 
not have initial antibiotics administered in the first six hours after wounding: there was 
no infection when antibiotics were administered within three hours.  
 
Two similarly designed observational studies have provided conflicting data on the 
significance of antibiotic timing. Petzakis and Wilkins reported that a delay in 
antibiotic administration of greater than three hours was associated with increased 
risk of wound infection24. Conversely, Al-Arabi et al. found that whilst a delay of 
greater than 24 hours until systemic antibiotic administration was associated with a 
higher risk of infection, delays of up to 24 hours were not58. However, neither study 
was able to control for the effect of different timing of surgery. 
 
While there remained a lack of definitive clinical evidence on the question of the 
timing of systemic antibiotics, the compelling data from animal studies supporting 
early administration and principal clinical guidelines currently advocate this 
position20,71.  
 
The findings of this study regarding the importance of initiating both antibiotic and 
surgical treatment early is consistent with previous work describing the progress of 
bacteria from its colonizing planktonic form to adherence to tissue and eventually the 
formation of biofilm, the so-called ‘race to the surface’72. As bacteria progress 
through these stages, the vulnerability to conventional treatments of debridement, 
irrigation and antibiotics decreases; the six hour time point appears to be 
significant73.    
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It is simpler to influence the timing of antibiotic initiation than surgery. This study, 
together with the existing literature, indicates that the earlier systemic antibiotics are 
administered the greater the effect on infection. It is reasonable to conclude that 
civilian Emergency Medical Services should follow their military counterparts and 
regard antibiotics as a key component of pre-hospital care of the casualty with an 
open fracture. Indeed, in instances where antibiotic administration has been delayed 
several hours, this study indicates that delaying surgery for up to 24 hours is likely to 
result in significantly greater infection rates compared to emergent surgery.  
Even when casualties receive very early antibiotics, this study supports the position 
that emergency surgical debridement can still reduce rates of infection. However, 




6.4 Are there novel treatments that might reduce infection in open fractures? 
This section of work aimed to test therapies with the potential to improve the 
treatment of open fractures and therefore reduce subsequent infection. The model 
development described in Chapter Three and evaluated earlier in this chapter 
ensured that the model was optimised to be sensitive to any effect in reducing rates 
of infection.  
 
6.4.1 Irrigation with chlorhexidine solution versus saline 
In this study a commonly used antiseptic, chlorhexidine, was evaluated as an 
irrigation fluid for reducing infection in open fractures. The study group with the 
lowest infection rate or quantity of bacteria in the wound was irrigated with 0.05% 
chlorhexidine followed by removal of antiseptic residue by rinsing with saline: this 
was superior than the control group but this difference did not reach significance. 
 
I conducted a post-hoc power analysis to determine whether this study was under-
powered. It indicated that study groups of 69 animals would have an 80% chance of 
demonstrating a statistically significant difference between them. I regarded this as 
an unacceptably large number of animals to use in an attempt to identify a very 
subtle difference. Being aware of the typical loss of effect as therapies are translated 
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from laboratory to clinical practice I did not think repeating the study with groups of 
animals of this size could be justified. 
 
The concentration of 0.05% chlorhexidine was selected for the “irrigate and rinse” 
group as this is the concentration that has been most thoroughly studied in the 
literature74-77. 
 
Lister’s practice of irrigating open fracture wounds with carbolic acid resulted in an 
unprecedented reduction in infections compared with the dire rates typical of the 
1860s78. In hindsight, much of his improved results might be attributed to the 
application of carbolic acid by the surgeon and to his instruments, and the 
development of antiseptic practice rather than the application of antiseptic directly 
into the wound. 
 
“Listerism,” as it became known, was the clinical standard until Fleming’s first great 
contribution to the management of open fractures: the recognition that the use of 
antiseptics in open fracture wounds actually increased bacterial loads. He ascribed 
this counter-intuitive observation to the toxicity of chemical antiseptics to the host 
immune system, which he thought was the most important factor in wound infection.  
 
The reason that many seemingly innocuous antiseptics are toxic in traumatic wounds 
can be explained by using the model proposed by Jackson in 1953 when he was 
working at the Birmingham Accident Hospital. This model divides the wounds into the 
inner zone of coagulation (necrotic tissue) and the peripheral zone of hyperaemia 
(inflamed tissue) divided by the zone of stasis, which is potentially viable but 
vulnerable to secondary insult79. Branemark later expanded on this work and 
demonstrated that the tissue in this zone of stasis is very sensitive to damage by 
antiseptics80.  
 
This conceptual model also explains the rebound phenomenon of bacterial load in a 
wound after irrigation with solutions other than saline. This was described in a paper 
by Owens et al. in a goat model of contaminated complex wounding81. Although the 
antiseptics and soap solutions removed more bacteria from the wound than saline 
initially, the wounds irrigated with solutions other than saline had higher levels of 
bacteria two days after debridement and irrigation. It is believed that tissue damage 
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caused by the irrigation solutions created an environment within the wound that 
allowed the bacteria to thrive.    
 
Because of the continuing challenge of infection in open fractures, investigators have 
continued to evaluate potential irrigation solutions. The benefit of inert fluids in 
physically rinsing bacteria from the wound should ideally be combined with a fluid 
with active antimicrobial properties that does not damage host tissue.  
 
Chlorhexadine is believed to offer this combination of bactericidal effect with low 
cytotoxicity and has been evaluated by a small number of studies. In a soft-tissue 
wound study, Platt et al. found that irrigation with a 0.05% Chlorhexidine solution was 
superior to 1% povidine iodine, 0.1% benzalkonium, and 0.9% saline at removing 
bacteria in a guinea pig contaminated dorsal wound model75.  
 
Various studies have evaluated the potential for chlorhexidine to have a negative 
effect on wound healing despite its beneficial effect in reducing bacterial loads. 
Brennan et al. found that there was no difference in rat wound healing or collagen 
production in a rat wound model exposed to saline or 0.05% chlorhexidine, whereas 
an adverse effect on both of these was associated with exposure to hypochlorite 
antiseptic 76. This study also found that 0.05% chlorhexidine and saline exerted a 
similarly negligible effect on microvascular flow to the wound77. However, Salami et 
al. found that rats with an uncontaminated full-thickness dorsal wound healed 
significantly faster when irrigated with saline than with chlorhexidine82. Conversely, in 
a recent in vitro study, Thomas et al. concluded that the negative effect on healing 
may only be significant when higher concentrations of chlorhexidine are used83. 
 
Of additional concern to orthopaedic surgeons is the chondrolytic effect of 
chlorhexidine that has been reported after the accidental use of it as an irrigation fluid 
during arthroscopy at both high84 and low concentrations85. A 2007 in vitro study 
using non-arthritic human cartilage suggests that there is no significant effect on 
cartilage health of a one minute exposure to 0.05% chlorhexidine86.  
 
Possibly because of these concerns about the effect on cartilage and wound healing, 
only one very limited clinical trial of chlorhexidine irrigation in orthopedic trauma has 
been performed. This trial compared irrigation with 0.05% chlorhexidine in closed hip 
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fractures with no irrigation and used bacterial quantification of intraoperative wound 
swabs as the outcome measure74. This very limited study demonstrated a small 
reduction in recovered bacteria, but statistical analysis was not provided. Small 
numbers of surgeons do use chlorhexidine to irrigate open fractures in their current 
clinical practice87. 
 
Anglen compared castile soap solution with bacitracin solution for the irrigation of 
lower extremity open fractures in 400 patients88. He found an insignificantly lower 
infection rate in the castile soap group and a significantly higher rate of wound 
breakdown in the bacitracin group. This study did not include irrigation with saline as 
a control. 
 
Most surgeons currently irrigate open fractures with low pressure saline87, a practice 
proved to be superior to irrigation with soap solution by a large multicenter 
randomised trial, the Fluid Lavage of Open Wounds (FLOW) study89.  
 
My results indicate that chlorhexidine at concentrations of 0.05% is the most superior 




6.4.2 Local antibiotic gel versus antibiotic polymethylmethacrylate ‘beads’ 
The results of this study demonstrate that local delivery of antibiotic by the 
bioabsorbable gel was more effective at reducing bacteria within a contaminated rat 
bone defect than the commonly used antibiotic polymethylmethacrylate (PMMA) 
bead method.   
 
Direct application of antimicrobial drugs into open fracture wounds is not a novel 
concept. In 1939, Jenson et al. presented their experience of treating open fractures 
with sulfanilamide powder poured directly into the wound prior to closure and credited 
introduction of this technique with a reduction in their infection rate from 30% to 5% 
90. The attraction of local delivery is that high concentrations of antibiotic can be 
achieved in the wound even in avascular areas, without the cost or toxic effects 
associated with systemically administered antibiotics.  
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Buchholz and colleagues in Germany first developed the use of PMMA cement 
blended with antibiotics in order to treat infected joint prosthesis91,92. This approach 
was then adapted to treat chronic osteomyelitis by Klemm who published his 
experiences in 197493. However, the only prospective randomized clinical trial of 
antibiotic PMMA beads in osteomyelitis did not find that they were superior in 
isolation or in combination with systemic antibiotics compared to systemic antibiotics 
alone in the treatment of osteomyelitis94.  
 
Despite this, there is some evidence that local antibiotics are effective at combating 
infection. In a 1990 case-series Henry et al. described the prophylactic use of 
antibiotic PMMA beads in addition to systemic antibiotics to reduce the infection rate 
in open fractures95. There were significantly less infections in the Gustillo-Anderson46 
II and III fractures treated with antibiotic-PMMA beads in comibination with systemic 
antibiotics compared to those who just received systemic antibiotics. In 1995 
Ostermann et al. published a similar comparison of 240 patients with open limb 
fractures who received intravenous (IV) antibiotics and 845 patients who received 
both IV antibiotics and antibiotic-PMMA beads at the fracture site. He found an 
infection rate of 12% in the IV only group compared to 3.7% in the IV/antibiotic-
PMMA bead group (p=0.001)96. It should be noted that neither of these studies 
randomised the treatment groups.  
 
Moehring et al. published the results of a prospective randomised trial designed to 
compare antibiotic PMMA beads with IV antibiotics in the prevention of infection in 
open fractures. This study described a trend toward superiority of antibiotic beads but 
it did not reach significance in the 67 patients studied97.   
 
Interestingly animal studies have also failed to convincingly establish a significant 
benefit of augmenting systemic antibiotics with antibiotic-PMMA beads in 
musculoskeletal infection98,99.  
 
Despite their widespread use, there is recognition that PMMA beads do not represent 
the ideal delivery vehicle for local antibiotics. They are bulky and not bioabsorbable, 
which potentially complicates wound closure and necessitates subsequent 
removal35,100.  This prevents their use during definitive closure of a wound.   
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In complex high-energy wounds, there is concern that the antibiotic eluting from the 
discrete depots of a PMMA bead will not diffuse sufficiently to reach all the recesses 
of a wound. This effect is potentially exacerbated by the concurrent use of negative 
pressure wound therapy101, which is well supported as a beneficial technique to 
reduce infection in open fractures102.  
 
There is also concern that self-manufactured PMMA beads have a varied and 
unpredictable antibiotic elution rate103. The commercially available antibiotic-PMMA 
beads Septopal® (Biomet, Bridgend, UK) contains gentamicin alone. However, when 
antibiotic-PMMA beads are manufactured de novo in the operating room, they are 
frequently formulated with both an aminoglycoside and vancomycin in order to 
ensure coverage of both gram positive and negative organisms35. This study 
mimicked this clinical practice and used both an aminoglycoside and vancomycin. 
 
Other local antibiotic delivery vehicles have been used: gentamicin-impregnated 
collagen sponges have been tested as a bioabsorbable vehicle. However, in a recent 
non-orthopaedic randomised clinical trial of CollaRx (Innocoll, Gallowston, Ireland), 
the sponge group had a higher rate of surgical site infection than the control group 
(30% versus 20%, p=0.01). It was speculated that the antibiotics eluted faster than 
the sponge degraded, leaving foreign material in the wounds without antibiotics104.  
 
Recent development work has focused on other absorbable antibiotic vehicles, 
including a range of synthetic bone grafts impregnated with antibiotics100. Osteoset 
‘T’ (Wright Medical, Arlington, TN, USA) are calcium sulphate pellets with 10% 
Tobramycin by weight. These have been used clinically to treat osteomyelitis, and 
have been found to be as effective at treating osteomyelitis as antibiotic delivery via 
PMMA beads, with a requirement for less surgery105,106. Other investigators have 
examined gel-based vehicles for delivering antibiotics in pre-clinical in vitro models of 
orthopaedic infection107. 
 
The ideal release profile for a local antibiotic delivery vehicle used to prevent 
infection in open fractures is not known. It is speculated that eluted local antibiotics 
should quickly rise above the Minimum Inhibitory Concentration (MIC) of relevant 
bacteria, be sustained above this level for several days, then rapidly drop to avoid 
bacteria being exposed to sub-inhibitory antibiotic concentration, thus promoting 
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resistance108. It is entirely possible that the ideal release profile of local antibiotic 
vehicles used for treating established osteomyelitis will be different and may require 
a more sustained release. 
 
It is possible that the observed differences between groups in my study is due to the 
alternative aminoglycocides used. It was decided to use tobramycin in the bead 
preparation as this study was testing the preparation against the current clinical 
standard. The initial work in Europe on delivery of antibiotics via PMMA beads in 
osteomyelitis involved gentamicin93. However, when this work was translated to 
infection prevention in open fractures in the US, tobramycin rather than gentamicin 
was used109 as until recently, this was the only aminogylcoside available in the US in 
powdered form35,110. Since this work was conducted in a US laboratory in 
collaboration with the US Department of Defence, I wanted to ensure my work was 
maximally relevant to my host’s clinical practice. The difference between the 
preparations was accepted in this study as it represented the clinical standard, and 
because the efficacy of gentamicin and tobramycin against gram positive bacteria in 
general is very similar111. 
 
A group was treated with both gel and beads as it was speculated that since 
antibiotic-PMMA cement is used by surgeons as a spacer to maintain soft tissues 
and eliminate dead space, there might be future utility in evaluating the compatibility 
of simultaneous antibiotic delivery by both gel and cement. The results from this 
group suggest that this is possible, but that it confers no additive antimicrobial effect.  
 
The differences in efficacy between the gel and beads is marked and may be due to 
the active amount of antibiotics released from each vehicle. A study that examined 
beads made using the same technique as this study found that only 20% of the total 
antibiotic was released within 60 days, but half of this was released in the first day112. 
Conversely, a bioabsorbable vehicle, such as the gel used in the study, will release 
100% of the carried antibiotics as it is degraded.  
 
The maximum antibiotic content of the beads used in these studies is limited by the 
dilution of the MMA co-polymer powder negatively affecting cement integrity113. In 
practice, this is a further advantage on the gel vehicle in that it enables greater 
quantities of antibiotic to be delivered, as shown in this study, where there was much 
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higher dosages of antibiotics in the animals treated with the gel. It is also possible 
that the superior performance of the gel is due to the improved distribution of 
antibiotic throughout the wound, rather than in discrete ‘pockets’ around the beads. 
This is due to the need for the active drug to elute and diffuse throughout the wound 
bed, compared to the gel’s immediate drug delivery to the entire wound contact area.  
 
I think that these results prove the concept of a bioabsorbable gel as a local antibiotic 
delivery vehicle capable of preventing infection in open fractures. Further evaluation 
is warranted to determine potential efficacy.  
 
 
6.4.3 Local Bismuth thiol gels in combination with systemic antibiotics 
Bacteria in biofilm can persist despite exposure to concentrations of antibiotics 100 to 
1,000 times greater than that which would inhibit planktonic bacteria114. For example, 
ampicillin demonstrated a minimum inhibitory concentration against Klebsiella 
pneumoniae of 2ug/ml in the standard planktonic conditions for this test. However, 
when grown as a biofilm, treatment of the identical strain with 5000ug/ml of ampicillin 
for four hours had very little effect on bacterial levels (much less than 1 log 
reduction). Conversely, the planktonically grown bacteria were completely eradicated 
at this dose115. 
 
This increased resistance of biofilms to antibiotics has also been observed in vivo, 
where experiments have demonstrated robust survival characteristics of adherent 
bacteria in wounds. Colonisation of experimental wounds challenged with clinical 
burn-isolated Pseudomonas aeruginosa resulted in populations of wound-adherent 
bacteria 500-fold more resistant to antibiotics than the non-adherent bacteria of the 
same strain in the same wound116.  
 
Unfortunately these biofilms can form very quickly117. In vitro experiments with clinical 
strains of Pseudomonas aeruginosa from human wounds have been shown to rapidly 
form adherent biofilms. These bacteria demonstrated adherence to surfaces within 
three hours, formation of visually recognizable biofilms within five hours, and mature 
biofilms within ten hours118.  
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The increased understanding of biofilms has explained three previously observed 
discrepancies related to infection and antibiotics. Firstly, there is a disparity between 
preclinical and clinical antibiotic efficacy. Secondly, if tissue levels of systemically 
administered antibiotics do not reach a critical threshold within the first four hours 
following injury, the ability to prevent bacterial adherence to the wound is impaired119. 
Thirdly, microbiological sampling techniques that rely on planktonic bacteria (e.g. 
swabs and joint aspirations) significantly under-detect the presence of bacteria.  
 
With this improved understanding of the true in vivo behavior of bacteria, novel 
strategies for eradication can be developed. One such approach is the combination 
of traditional systemic antibiotics (at a typical dosage sufficient to inhibit planktonic 
bacteria) with a novel local treatment to inhibit bacterial adherence and formation of 
microbial biofilms in wounds. 
 
In a recent study, MB-8-2 (bismuth-2,3-butanedithiol/Bismuth-2-mercaptopyridine N-
oxide) achieved a >4.9 log reduction in methicillin-resistant Staphylococcus aureus 
(MRSA) biofilm and a 6.2 log reduction in Pseudomonas aeruginosa biofilms when 
tested in a drip-flow biofilm system120.   
 
Other Bismuth Thiols (BTs) have also been shown to inhibit and/or disrupt biofilm. 
Against staphylococci, bismuth dimercaptotoluene (BisTOL) reduces slime 
production by >90% at 1.25µM (0.25µg/ml), without appreciably inhibiting bacterial 
growth121. Biofilms and exopolysaccharides produced by Pseudomonas species are 
also inhibited at sub-growth concentrations of BT122,123. Indeed, several major 
virulence factors in P. aeruginosa were mitigated by low concentrations of BisEDT, 
including resistance to serum bactericidal activity, resistance to phagocytosis, and 
adherence to collagen matrix122. By dismantling the protective biofilm matrix, BTs, 
including MB-8-2, may augment therapy both by enhancing immune defenses and by 
promoting antibiotic activity though inhibition and dismantling of biofilm. 
 
The study for this thesis screened three BT formulations known to inhibit or eradicate 
bacterial biofilms for in vivo effectiveness when used with systemic antibiotics. One 
BT in particular (MB-8-2) was selected for further characterisation based on my 
judgement of it exhibiting the most promising balance of toxicity and anti-bacterial 
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effect. An optimum dose of this BT formulation was identified, and a marked 
enhancement of the effect of systemic antibiotics was demonstrated.  
 
I think that these results echo the findings of other investigators who have examined 
the effect of local antiseptics on wound infection33,124. Specifically, there is a balance 
between the concentration required to be toxic to bacteria, and the concentration that 
becomes toxic to wound tissue and therefore impairs the host’s ability to respond to 
infection. This study defined this “therapeutic window” for this model. 
 
These findings indicate that local BTs can increase the effectiveness of systemic 
antibiotics on bacteria in an open fracture wound. Preventing biofilm formation, 
disrupting existing biofilm, and sensitising bacteria to attack by antimicrobial agents 
and immune defences may mean that BTs are a potential technique for fighting 
biofilm-related infections, including wound infections. The use of BTs in combination 
with other agents (including those that have lost their effectiveness) has the potential 




This thesis describes a range of studies conducted in order to answer a series of 
questions. Initially broad concepts of survival and how this is measured were 
examined, before the work moved on to focus on a specific clinical problem and the 
development of potential treatments for infection associated with open fractures. 
 
The initial work confirmed the belief that survival had improved over the course of the 
conflicts in Iraq and Afghanistan. As part of these efforts, the methodology for 
measuring survival after combat injury was refined. Registry data was used to 
quantify how common open fractures were, and the most frequently occurring of 
these, open tibia fractures, were examined in more detail. The infection rate for these 
injuries was established at 23%, with 60% of these infections due to S. aureus. 
 
A rodent femur fracture inoculated with S. aureus was used to model contaminated 
open fractures. This model was refined to incorporate systemic antibiotics and a 
bacterial inoculation that resulted in a 50% infection rate. Using this refined model, 
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the relationship between the timing of antibiotic and surgical treatment was 
characterised and the importance of early antibiotic administration established.  
 
Wound irrigation with the antiseptic solution chlorhexidine was evaluated, and was 
found not to be superior to saline. Antibiotic gel was found to be a more effective 
vehicle for delivery of local antibiotics than polymethylmethacrylate beads. Finally, a 
novel anti-bacterial biofilm treatment in the form of topical Bismuth-Thiol preparation 
was shown to potentiate systemic antibiotics. These last two studies lay the 
foundation for translational and clinical studies of local antibiotics and Bismuth Thiols. 
 
This thesis has demonstrated that there is still much work to be done to improve the 
reconstruction and rehabilitation of those recovering from combat injury. However, 
this is a problem resulting from the significant improvements in survival and therefore 
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